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Introduction {#sec001}
============

Endometrium is a dynamic tissue whose cellular components undergo cyclic proliferation and differentiation, preparing for embryo implantation by highly coordinated spatiotemporal actions of ovarian-derived estradiol (E~2~) and progesterone (P~4~) \[[@pgen.1008601.ref001],[@pgen.1008601.ref002]\]. These hormones bind cognate receptors \[estrogen receptor (ER) and progesterone receptor (PR)\], whose activities are tightly regulated by post-translational modifications and interactions with cell- and tissue-specific co-regulators \[[@pgen.1008601.ref003]--[@pgen.1008601.ref005]\]. Binding ER and PR leads to their nuclear translocation, complexing with nuclear response elements, remodeling chromatin by co-modulator recruitment \[[@pgen.1008601.ref003]\], and alteration of the transcriptional machinery. In endometrium, dynamic circulating E~2~ and P~4~ levels drive the normal functionality of the tissue. Moreover, environmental and inflammatory signals can alter steroid hormone-driven endometrial gene transcription and cellular function resulting in tissue dyshomeostasis \[[@pgen.1008601.ref006]\], including endometrial hyperplasia and cancer, endometrial-based infertility, endometriosis, and poor pregnancy outcomes \[[@pgen.1008601.ref007],[@pgen.1008601.ref008]\]. While changes in chromatin accessibility, PR targets and changes in histones and gene expression in eSF decidualization by E~2~, cAMP and MPA have been shown \[[@pgen.1008601.ref009]--[@pgen.1008601.ref011]\], how E~2~ and P~4~ individually interact with the endometrial epigenome normally or in inflammatory disorders that compromise endometrial function, e.g., as in the disorder endometriosis, are incompletely understood. We *hypothesized* that these steroid hormones induce unique genome-wide signatures in normal human endometrial stromal fibroblasts with aberrant signatures in endometrial cells from women with endometriosis, and their effect on the epigenome is directed by specific genomic sequences and locations.

Endometriosis is a common, chronic disorder wherein endometrial tissue, shed into the pelvis at menses, elicits an inflammatory response, neuroangiogenesis and fibrosis, resulting in infertility and chronic pelvic pain \[[@pgen.1008601.ref012]\]. Hallmarks of the disorder are its dependence on E~2~ for growth, disrupted P~4~ signaling caused by chronic inflammation in endometriosis lesions and in the eutopic endometrium (uterine lining) \[[@pgen.1008601.ref013]\], and epigenetic chromatin changes that determine endometrial cellular responses to mitogenic and differentiative signals \[[@pgen.1008601.ref006],[@pgen.1008601.ref012],[@pgen.1008601.ref014]\]. Normally, the eutopic endometrial DNA methylome varies according to the hormonal milieu, with greatest differences in the E~2~-dominant (proliferative) versus P~4~-dominant (secretory) phase of the cycle and associated with gene expression changes \[[@pgen.1008601.ref010],[@pgen.1008601.ref013]--[@pgen.1008601.ref016]\]. Chronic inflammation affects the chromatin landscape in endometrium of women and animal models of endometriosis \[[@pgen.1008601.ref006]\]. These observations on bulk tissue raise fundamental questions about steroid hormone-epigenome interactions in cellular components of the endometrium normally and in women with disease, how steroid hormones affect the epigenome, how the epigenome affects steroid hormone response and action, and if there are epigenetic differences in endometrium of women with endometriosis and different stages of disease, and if so, what role they play in these processes.

Herein, we studied responses of endometrial stromal fibroblasts (eSF) isolated from *normal* women (controls) and those with endometriosis. eSF comprise a major endometrial cell type whose programmed responses to E~2~ and P~4~ are essential for pregnancy success and whose responses are compromised in inflammatory disorders \[[@pgen.1008601.ref017]\], including endometriosis \[[@pgen.1008601.ref018],[@pgen.1008601.ref019]\]. Given the centrality of a normal eSF P~4~ response for pregnancy and that women with endometriosis have infertility and poor pregnancy outcomes reported by some to be due, in part, to altered eSF basal gene expression and abnormal response to P~4~ \[[@pgen.1008601.ref018]--[@pgen.1008601.ref021]\]~,~ understanding steroid hormone-signaling and regulation of transcription in this cell type is paramount. Moreover, controls for this study were women with no known gynecologic or systemic disorders, thereby enabling establishment of a normative platform for steroid hormone effects on the epigenome and gene transcription in this cell type in endometrium, the tissue that is the anatomic pre-requisite for continuation of the species.

Results {#sec002}
=======

Distinct Effects of Ovarian Steroid Hormones in *Normal Human Endometrium* {#sec003}
--------------------------------------------------------------------------

We assessed the genome-wide effect of individual steroid hormones, E~2~ and P~4~, and their combination (E~2~+ P~4~) on endometrial stromal fibroblasts (eSF) after 14 days of exposure mimicking the timeframe in the menstrual cycle for maximal hormone responsiveness. Since the effects of E~2~ and P~4~ individually and together on the hormone-epigenome interplay in *normal* endometrial cells was unknown and was a main aim of this study, we applied stringent criteria and utilized only endometrial samples from extensively screened volunteers without any gynecologic disorders and no uterine pathology (NUP), with confirmed *in vitro* eSF progesterone responsiveness (see [methods](#sec026){ref-type="sec"} and **[S1 Fig](#pgen.1008601.s001){ref-type="supplementary-material"}**).

Interrogation of 485,577 methylation targets across the genome revealed that E~2~ and P~4~ and their combination affected the DNA methylome to different extents and with distinct patterns in eSF~normal~. (Note: throughout the Results section steroid responses of eSF DNA methylomes are compared to untreated (vehicle) cells for each group.) E~2~ induced the most extensive changes in the eSF~normal~ DNA methylome (2047 CpG sites), followed by combined E~2~+P~4~ (569 CpG sites), and P~4~ alone had the least effect (505 CpG sites) (**[Fig 1A and 1B](#pgen.1008601.g001){ref-type="fig"}, [S1 Table](#pgen.1008601.s004){ref-type="supplementary-material"}**). Importantly, combined E~2~+P~4~ resulted in dramatically reduced numbers of differentially methylated loci compared to E~2~ alone (**[Fig 1A](#pgen.1008601.g001){ref-type="fig"}**). While individual hormone treatments elicited hormone-specific DNA methylome changes, the simultaneous presence of both hormones altered their individual effects. The pattern of loss and gain of methylation is also distinct for each hormone. E~2~, and E~2~+P~4~ induced more loss than gain of methylation (**[Fig 1A](#pgen.1008601.g001){ref-type="fig"},** yellow: gain of methylation, blue: loss of methylation vs vehicle), while P~4~ induced similar numbers of loss and gain of methylation. Concordant with differential patterns and extents of methylation changes, we found minimal overlap in the differentially methylated CpG sites affected by each hormone and the majority was unique (**[Fig 1C](#pgen.1008601.g001){ref-type="fig"}**, **[S1 Table](#pgen.1008601.s004){ref-type="supplementary-material"}**). In particular, loci differentially methylated in response to E~2~+P~4~ were mostly unique compared to those in response to P~4~ or E~2~ alone and were not a combination of the response to each hormone individually (**[Fig 1C](#pgen.1008601.g001){ref-type="fig"}**).

![Hormone induced differentially methylated CpG sites in [normal eSF (NUP)]{.ul}.\
**1A.** Differentially methylated CpG sites induced by E~2~, P~4~ and E~2~+P~4~ versus vehicle. Each heatmap reflects differential methylation of each sample in each hormone treatment versus its corresponding non-treated vehicle control (Δβ: Hormone treated minus vehicle control). Yellow heatmaps above the X-axis reflect gain of methylation vs. vehicle; blue heatmaps below the X-axis reflect Δβ loss of methylation. In each heatmap, rows show Δβ of differentially methylated loci, columns indicate samples. Y-axis shows the number of differentially methylated loci for either gain or loss of methylation for each hormone treatment. **1B.** Number of differentially methylated CpG sites and in gain/loss of methylation for each hormone treatment. **1C.** Venn diagram of unique and common differentially methylated CpG sites for each hormone shows little overlap between differentially methylated loci in each hormone treatment **1D.** Enrichment of intergenic regions in % in each hormone treatment for all differentially methylated loci (All Loci), those with gain or loss of methylation (Gain, Loss) and by individual hormones (E~2~, P~4~, E~2~+P~4~). Enrichment is assessed by Z-test and p\<0.05 are shown in parentheses. Black bar represents percentage of intergenic loci of total interrogated CpG sites. **1E.** Statistically significant involvement of enhancers by hormones and gain or loss of methylation. Enrichment is assessed by Z-test and p\<0.05 are shown in parentheses. Black bar represents percentage of enhancers of total interrogated CpG sites. **1F.** Genomic distribution of all differentially methylated CpG sites in each hormone and by gain or loss of methylation, assessed at TSS1500, TSS200, 5'UTR, 1^st^ exon, gene body, 3'UTR, and intergenic regions. Black line represents the percentage of interrogated CpG site at each location, green line (top panel) shows all differentially methylated loci in NUP for all hormones, yellow line (middle panel) shows all loci with gain of methylation in NUP, and blue line (bottom panel) shows all loci with loss of methylation for all hormones. Enrichment is assessed by Z-test and p\<0.05 are shown in parentheses for each genomic location. **1G.** Distribution of differentially methylated CpGs by CpG islands (CGI), CGI north/south shores and shelves for all loci with gain of methylation in all hormone treatments (orange lines) or with loss of methylation (blue line) in comparison to the distribution of the interrogated CpG sites in each of these genomic locations (black line). N Shelf: North Shelf; S Shelf: South Shelf; N Shore: North Shore; S Shore: South Shore. NUP: normal (no uterine pathology).](pgen.1008601.g001){#pgen.1008601.g001}

Pathways and biofunctions (**[Table 1](#pgen.1008601.t001){ref-type="table"}**) as well as functional enrichment clustering **([Table 2](#pgen.1008601.t002){ref-type="table"})** were also unique to each hormone with E~2~ pathways enriching for gap junctions, melanogenesis, and glutamatergic and dopaminergic synapses pathways, and zinc and ion binding, cell membrane, glycoprotein and signal peptide functional clusters, with fewer and unique statistically significant pathways and functional clusters affected by P~4~ and E~2~+P~4~. Together these data indicate that each hormone affects different regions and E~2~+P~4~ targets are not a combination of E~2~ and P~4~. Differentially methylated loci in all hormonally treated eSF~normal~ involved several pathways, many important in normal endometrial function and dysfunction. Important pathways affected by each hormone and the differentially methylated genes in each pathway are shown in **[S1 Data](#pgen.1008601.s022){ref-type="supplementary-material"}.** The data were further mined for differences in DNA methylation patterns, profiles, and genomic locations, regulatory elements, transcribed genes and biofunctions induced by each hormonal treatment in cells from normal and endometriosis women (see below).

10.1371/journal.pgen.1008601.t001

###### Pathways associated with differentially methylated (DM) transcribed loci in each hormonal treatment (E~2~, P~4~, E~2~+P~4~) vs. vehicle in normal (NUP), stage I (Endo I) and stage IV (Endo IV).

![](pgen.1008601.t001){#pgen.1008601.t001g}

  Pathways in each hormone treatment   NUP (P-Values \<0.05, *Enriched but P\>0.05*)                                                                                                                                                                                                                                                                                                                                                                                                                                                                Endo I (P-Values \<0.05, *Enriched but P\>0.05*)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Endo IV (P-Values \<0.05, *Enriched but P\>0.05*)
  ------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  E~2~ vs. Veh                         Gap junction (0.015), Long-term potentiation (0.016), Long-term depression (0.025), Melanogenesis (0.035), Glutamatergic synapse (0.038), Dopaminergic synapse (0.041), *Sphingolipid signaling pathway (0.053), Ubiquitin mediated proteolysis (0.064), cGMP-PKG signaling pathway (0.07), Thyroid hormone signaling pathway (0.077), Retrograde endocannabinoid signaling (0.078), Cell adhesion molecules (CAMs) (0.08), mRNA surveillance pathway (0.092), Vascular smooth muscle contraction (0.097)*   MAPK signaling pathway (0.00052), cGMP-PKG signaling pathway (0.0014), PI3K-Akt signaling pathway (0.0019), Focal adhesion (0.0025), Axon guidance (0.0049), ECM-receptor interaction (0.0058), Oxytocin signaling pathway (0.012), Melanoma 0.015 Platelet activation (0.015), ErbB signaling pathway (0.017), Gap junction (0.018), Long-term depression (0.018), Amoebiasis (0.022), AMPK signaling pathway (0.022), Olfactory transduction (0.024), Renin secretion (0.025), Choline metabolism in cancer (0.039), Arrhythmogenic right ventricular cardiomyopathy (ARVC) (0.041), T cell receptor signaling pathway (0.044), Protein digestion and absorption (0.046), *VEGF signaling pathway (0.057), Cell adhesion molecules (CAMs) (0.058), Inflammatory bowel disease (IBD) (0.069), Proteoglycans in cancer (0.071), Renal cell carcinoma (0.074), HIF-1 signaling pathway (0.077), Ubiquitin mediated proteolysis (0.093), Regulation of actin cytoskeleton (0.098)*   Term P-Value Melanoma (0.00043), Signaling pathways regulating pluripotency of stem cells (0.00069), Proteoglycans in cancer (0.0018), Estrogen signaling pathway (0.012), Glioma (0.012), Choline metabolism in cancer (0.013), Olfactory transduction (0.022), ErbB signaling pathway (0.032), Prostate cancer (0.034), Endometrial cancer (0.035), Ras signaling pathway (0.037), GnRH signaling pathway (0.037), FoxO signaling pathway (0.038), Non-small cell lung cancer (0.042), *MAPK signaling pathway (0.064), Endocytosis (0.067), Cholinergic synapse (0.068), Fc epsilon RI signaling pathway (0.068), Oxytocin signaling pathway (0.068), Rap1 signaling pathway (0.071), Neurotrophic signaling pathway (0.085), RNA degradation (0.091), Pathways in cancer (0.095)*
  P~4~ vs. Veh                         *Staphylococcus aureus infection (0.071), MAPK signaling pathway (0.084), Tuberculosis (0.095), Tight junction (0.097)*                                                                                                                                                                                                                                                                                                                                                                                      Pathways in cancer (0.015), Cell adhesion molecules (CAMs) (0.02), Glutamatergic synapse (0.028), Toxoplasmosis (0.032), Cocaine addiction (0.037), *Steroid hormone biosynthesis (0.056), Phototransduction (0.062), Inflammatory bowel disease (IBD) (0.071), Serotonergic synapse (0.086), Chronic myeloid leukemia (0.094)*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Non-small cell lung cancer (0.00031), Prostate cancer (0.00033), Glioma (0.00062), Endometrial cancer (0.0022), Thyroid hormone synthesis (0.0065), Melanoma (0.0069), Glutamatergic synapse (0.0073), Calcium signaling pathway (0.012), ErbB signaling pathway (0.014), MAPK signaling pathway (0.019), Proteoglycans in cancer (0.02), Estrogen signaling pathway (0.021), Acute myeloid leukemia (0.022), Pathways in cancer (0.024), Long-term depression (0.026), Cholinergic synapse (0.031), Pancreatic cancer (0.032), Amphetamine addiction (0.033), Chronic myeloid leukemia (0.042), Dopaminergic synapse (0.048), *FoxO signaling pathway (0.055), cAMP signaling pathway (0.06), Gap junction (0.068), Viral carcinogenesis (0.068), Hepatitis B (0.069) Adrenergic signaling in cardiomyocytes (0.071), Bladder cancer (0.071), GnRH signaling pathway (0.073), Rap1 signaling pathway (0.074), Oxytocin signaling pathway (0.089), Choline metabolism in cancer (0.094), Cocaine addiction (0.096)*
  E~2~+ P4 vs Veh                      Morphine addiction (0.022), *Steroid hormone biosynthesis (0.082), Long-term depression (0.089)*                                                                                                                                                                                                                                                                                                                                                                                                             Focal adhesion (0.00097), ECM-receptor interaction (0.0019), PI3K-Akt signaling pathway (0.0087), Glutamatergic synapse (0.0099), Toxoplasmosis (0.012), FoxO signaling pathway (0.024), Dorso-ventral axis formation (0.033), Arrhythmogenic right ventricular cardiomyopathy (ARVC) (0.038), *Hypertrophic cardiomyopathy (HCM) (0.053), Dilated cardiomyopathy (0.069), NF-kappa B signaling pathway (0.077)*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Transcriptional mis-regulation in cancer (0.012), PI3K-Akt signaling pathway (0.043), *AMPK signaling pathway (0.051), Epstein-Barr virus infection (0.066), Prostate cancer (0.079), Type I diabetes mellitus (0.083), Taste transduction (0.093)*

10.1371/journal.pgen.1008601.t002

###### Comparison of Functional Enrichment clusters in normal, stage I and stage IV in each hormone treatment (E~2~, P~4~, E~2~+P~4~) vs. vehicle.
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  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                            Normal                                                                                                                                                                                  Stage I                                                                                                                                                                               Stage IV
  ----------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **E**~**2**~ **Treatment**                4 clusters (Enrichment Score ≥2)\                                                                                                                                                       6 clusters (Enrichment Score ≥2)\                                                                                                                                                     Only 1 cluster (Enrichment Score ≥2)\
                                            1) 255 loci: zinc/zinc ion binding, metal binding\                                                                                                                                      1) 449 loci: Cell membrane, cytoplasmic, glycoprotein, membrane, transmembrane\                                                                                                       1) 135 loci: signal peptide, Receptor, Signal, disulfide bond, Cell membrane, Extracellular, Cytoplasmic, plasma membrane, glycosylation site: N-linked, Glycoprotein, integral component of membrane, transmembrane region, Transmembrane helix, Membrane
                                            2) 576 loci: disulfide bond, signal peptide, Cell membrane, Signal, Extracellular, Glycoprotein\                                                                                        2) 13 loci: SAM\                                                                                                                                                                      
                                            3) 14 loci: TK\                                                                                                                                                                         3) 48 loci: synapse/cell junction\                                                                                                                                                    
                                            4) 19 loci: Spectrins, Spectrin/alpha-actinin, Calponin homology domain, CHs, Actin-binding, Actinin-type, DNA replication, recombination, and repair                                   4) 20 loci: Fibronectin types\                                                                                                                                                        
                                                                                                                                                                                                                                    5) 301 loci: disulfide bond, signal peptide, Signal, Glycoprotein\                                                                                                                    
                                                                                                                                                                                                                                    6) 16 loci: PDZ                                                                                                                                                                       

  **P**~**4**~ **Treatment**                2 (+ 1) clusters (Enrichment Score ≥2)\                                                                                                                                                 4 clusters (Enrichment Score ≥2)\                                                                                                                                                     2 clusters (ES 2.9 and ES 1.99)\
                                            1) 18 loci: Pleckstrin homology domain, PH\                                                                                                                                             1) 25 loci: Synapse, cell junction\                                                                                                                                                   1) 24 loci: Cadherins, calcium ion binding, homophilic cell adhesion via plasma membrane adhesion molecules, Calcium, Cell adhesion\
                                            2) 31 loci: PH1, PH2, guanyl-nucleotide exchange factor activity, regulation of small GTPase mediated signal transduction, positive regulation of apoptotic process,\                   2) 34: Cadherins, cell adhesion\                                                                                                                                                      2) 14 loci: postsynaptic density, Postsynaptic cell membrane, cell junction, Synapse, Cell junction
                                            Dbl homology (DH) domain, RhoGEF, Rho guanyl-nucleotide exchange factor activity, regulation of Rho protein signal transduction, DH,\                                                   3) 149: in Extracellular, Cell membrane, plasma membrane, Cytoplasmic, glycosylation site: N-linked, transmembrane region, integral component of membrane, Transmembrane, membrane\   
                                            Guanine-nucleotide releasing factor, positive regulation of GTPase activity, Pleckstrin homology-like domain\                                                                           4) 7: SAM                                                                                                                                                                             
                                            3) (ES = 1.99) 100 loci: topological domain: Cytoplasmic, Cell membrane, plasma membrane                                                                                                                                                                                                                                                                                      

  **E**~**2**~**+P**~**4**~ **treatment**   NO clusters of ES≥2; 2 clusters of 1.61\                                                                                                                                                6 clusters (Enrichment Score ≥2)\                                                                                                                                                     E2/P4: 1 cluster (Enrichment Score ≥2)\
                                            1) 126 loci: transcription factor activity, sequence-specific DNA binding, DNA binding, regulation of transcription, DNA-templated, nucleoplasm, Transcription/T regulation, Nucleus\   1) 14: PDZ, PDZ domain\                                                                                                                                                               1) 24 loci: Fibronectins, Immunoglobulin-like fold
                                            2) 3 loci: Diacylglycerol kinase, catalytic domain, ATP-NAD kinase-like domain, DAGKc                                                                                                   2) 49: EGF, EGF-like, EGF-like Ca binding\                                                                                                                                            
                                                                                                                                                                                                                                    3) 21: ECM-receptor interaction; Focal adhesion; PI3K-Akt signaling pathway\                                                                                                          
                                                                                                                                                                                                                                    4) 43: postsynaptic density, Postsynaptic cell membrane, Synapse, cell junction,\                                                                                                     
                                                                                                                                                                                                                                    5) 24: Spectrins, Actin/actin-binding, Spectrin/alpha-actinin\                                                                                                                        
                                                                                                                                                                                                                                    6) 264:: Extracellular, cell membrane, Glycoprotein, transmembrane/ transmembrane region                                                                                              
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Genomic locations, regulatory elements, CpG islands and neighborhood context {#sec004}
----------------------------------------------------------------------------

Interestingly, while the patterns, profiles, differentially methylated CpG sites, pathways and biofunctions were unique to each hormone, the genome-wide distribution of their affected CpG sites shows specific enrichments and depletions. All hormones (E~2~, P~4~ and E~2~+P~4~) were statistically significantly enriched in intergenic regions (**[Fig 1D](#pgen.1008601.g001){ref-type="fig"})** and in enhancers (**[Fig 1E](#pgen.1008601.g001){ref-type="fig"})**, albeit with different extents and in gain vs loss of methylation and some variations based on hormones. These may reflect hormone binding sites in these regions, as had been reported in breast cancer cell lines \[[@pgen.1008601.ref022],[@pgen.1008601.ref023]\]. There was a marked depletion of differential methylation in close proximity to transcription start sites (TSS) up to -200 nt upstream (TSS200) for all hormonal treatments in both of gain or loss of methylation (**[Fig 1F](#pgen.1008601.g001){ref-type="fig"}**; **[S2 Fig](#pgen.1008601.s002){ref-type="supplementary-material"}** for gain/loss for each hormone**; [S2 Table](#pgen.1008601.s005){ref-type="supplementary-material"}**). But, CpG sites with gain of methylation in all hormonal treatments exhibited low enrichment at 5'UTRs, 1^st^ exons and gene bodies, while in loss of methylation TSS1500 and 1^st^ exons were less involved but gene bodies and 3'UTRs were more enriched. Greatest differences in gain versus loss of methylation (**[Fig 1F](#pgen.1008601.g001){ref-type="fig"}**) involved gene bodies, and 3'UTRs, and less at TSS1500, TSS200, 5'UTRs, and 1^st^ exons.

*CpG islands (CGI)*, *CGI shores and shelves*. For all hormones, there was low involvement of CGIs and CGI shelves and shores, compared to interrogated loci on the HM450 platform (**[Fig 1G](#pgen.1008601.g001){ref-type="fig"}** and **[S3 Table](#pgen.1008601.s006){ref-type="supplementary-material"}**). Most DNA methylation changes in eSF~normal~ did not involve CGIs. Indeed, while 31% of all interrogated loci were at CGIs and 33% at CGI shores and shelves (total CGI-related 64%), only 5--7% of the differentially methylated loci for any hormonal treatment were located at CGIs (33--40% overall in CGIs, shores and shelves, compared to 64% arrayed on the platform). The majority of differentially methylated CpG sites involved non-CGIs (59--66%) versus 36% non-CGI CpG sites on the platform. However, there were more differentially methylated CpG sites at CGI shores and shelves than in CGIs, in both gain and loss of methylation. Notably, more CGIs, less CGI shelves (north and south shelves), more CGI shores (north and south shores), and less non-CGI CpG sites were involved in gain versus loss of methylation.

Changes in gene expression in response to hormones {#sec005}
--------------------------------------------------

Steroid hormones affect their target genes through various mechanisms and as such, changes in DNA methylation may not fully reflect their effect on changes in gene expression, particularly in the case of those loci whose transcriptional regulation does not involve chromatin modifiers. To elucidate a more complete effect of hormones, transcriptomic profiles were determined in the same steroid hormone-treated eSF used for DNA methylation analysis and was compared to its corresponding gene expression profiles in untreated eSF. E~2~ induced more up- than down-regulated genes (**[Table 3](#pgen.1008601.t003){ref-type="table"},** top up- and down-regulated loci; **[S4 Table](#pgen.1008601.s007){ref-type="supplementary-material"},** full gene list), and P~4~ elicited similar numbers of up- and down-regulated genes, (**[S4 Table](#pgen.1008601.s007){ref-type="supplementary-material"}**). However, more genes were differentially expressed when E~2~ and P~4~ were combined, with more genes up- than down-regulated (**[S4 Table](#pgen.1008601.s007){ref-type="supplementary-material"}**).

10.1371/journal.pgen.1008601.t003

###### Top up/down regulated differentially expressed genes in response to each hormone treatment (E~2~, P~4~, E~2~+P~4~) vs. vehicle in normal (NUP), stage I (Endo I) and stage IV (Endo IV).
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  Transcripts Cluster Id                Gene symbol   Fold change   Regulation   Chr.    Entrez gene                 Gene Description
  ------------------------------------- ------------- ------------- ------------ ------- --------------------------- --------------------------------------------------------------------------------------------------------
  **NUP_E2 vs Veh**                                                                                                  
  7965873                               IGF1          21.46         up           chr12   3479                        insulin-likegrowthfactor1(somatomedin C)
  8040292                               GREB1         8.19          up           chr2    9687                        growthregulationbyestrogeninbreastcancer1
  7951165                               **PGR**       4.78          up           chr11   5241                        Progesterone receptor
  7971461                               LCP1          4.70          up           chr13   3936                        lymphocytecytosolicprotein1(L-plastin)
  8101659                               SPARCL1       4.60          up           chr4    8404                        SPARC-like1(hevin)
  8088560                               ADAMTS9       3.81          up           chr3    56999                       ADAMmetallopeptidasewiththrombospondintype1motif,9
  7987315                               ACTC1         3.79          up           chr15   70                          actin, alpha, cardiacmuscle1
  8107823                               ADAMTS19      3.13          up           chr5    171019                      ADAMmetallopeptidasewiththrombospondintype1motif,19
  8086352                               ULK4          3.00          up           chr3    54986                       unc-51likekinase4
  8080562                               IL17RB        2.91          up           chr3    55540                       interleukin17receptorB
  7965335                               DUSP6         -2.08         down         chr12   1848                        dualspecificityphosphatase6
  7917561                               GBP4          -2.09         down         chr1    115361                      guanylatebindingprotein4
  8146863                               SULF1         -2.11         down         chr8    23213                       sulfatase1
  8097692                               EDNRA         -2.18         down         chr4    1909                        Endothelin receptor type A
  7921916                               RGS5          -2.25         down         chr1    8490                        regulatorofG-proteinsignaling5
  7968417                               FRY           -2.32         down         chr13   10129                       Furry homolog (Drosophila)
  7909503                               SERTAD4       -2.41         down         chr1    56256                       SERTAdomaincontaining4
  8067969                               CHODL         -2.46         down         chr21   140578                      chondrolectin
  8006433                               CCL2          -2.84         down         chr17   6347                        chemokine(C-C motif) ligand2
  7906919                               RGS4          -3.58         down         chr1    5999                        regulatorofG-proteinsignaling4
  **NUP_P4 vs Veh**                                                                                                  
  8089145                               ABI3BP        14.27         up           chr3    25890                       ABI family, member3(NESH)binding protein
  8101659                               SPARCL1       13.19         up           chr4    8404                        SPARC-like1(hevin)
  8155864                               RORB          5.17          up           chr9    6096                        RAR-related orphan receptor B
  7965873                               IGF1          4.61          up           chr12   3479                        insulin-likegrowthfactor1(somatomedin C)
  7977933                               SLC7A8        4.31          up           chr14   23428                       solutecarrierfamily7(amino acid transporter light chain, L system), member 8
  8138231                               THSD7A        4.11          up           chr7    221981                      thrombospondin, type I, domaincontaining7A
  8132694                               IGFBP1        3.87          up           chr7    3484                        insulin-likegrowthfactorbindingprotein1
  7971461                               LCP1          3.70          up           chr13   3936                        lymphocytecytosolicprotein1(L-plastin)
  8122099                               ENPP1         3.22          up           chr6    5167                        Ectonucleotide pyrophosphatase/phosphodiesterase1
  8043995                               IL1R1         3.21          up           chr2    3554                        interleukin1receptor, type I
  8046048                               CSRNP3        -2.07         down         chr2    80034                       cysteine-serine-richnuclearprotein3
  7923978                               CD34          -2.09         down         chr1    947                         
  8166747                               SYTL5         -2.10         down         chrX    94122                       synaptotagmin-like5
  7945680                               H19           -2.17         down         chr11   283120///100033819///6206   H19, imprintedmaternallyexpressedtranscript(non-proteincoding)\|microRNA675\|ribosomalproteinS12
  7917561                               GBP4          -2.25         down         chr1    115361                      guanylatebindingprotein4
  8150428                               SFRP1         -2.29         down         chr8    6422                        secretedfrizzled-relatedprotein1
  8146863                               SULF1         -2.30         down         chr8    23213                       sulfatase1
  8102587                               NDNF          -2.31         down         chr4    79625                       neuron-derived neurotrophic factor
  8138289                               ETV1          -2.66         down         chr7    2115                        etsvariant1
  8006433                               CCL2          -2.73         down         chr17   6347                        Chemokine (C-C motif) ligand2
  **NUP_E2+P4 vs Veh**                                                                                               
  8101659                               SPARCL1       53.10         up           chr4    8404                        SPARC-like1(hevin)
  8089145                               ABI3BP        37.91         up           chr3    25890                       ABI family, member3 (NESH) binding protein
  8132694                               IGFBP1        24.11         up           chr7    3484                        insulin-likegrowthfactorbindingprotein1
  8155864                               RORB          17.01         up           chr9    6096                        RAR-related orphan receptor B
  8040292                               GREB1         15.10         up           chr2    9687                        growthregulationbyestrogeninbreastcancer1
  7977933                               SLC7A8        13.95         up           chr14   23428                       solutecarrierfamily7(amino acid transporter light chain, L system), member 8
  7965873                               IGF1          13.61         up           chr12   3479                        insulin-likegrowthfactor1(somatomedin C)
  8138231                               THSD7A        10.44         up           chr7    221981                      thrombospondin, type I,domaincontaining7A
  8144917                               LPL           8.89          up           chr8    4023                        Lipoprotein lipase
  7971461                               LCP1          8.88          up           chr13   3936                        lymphocytecytosolicprotein1(L-plastin)
  8055323                               NCKAP5        -3.31         down         chr2    344148                      NCK-associatedprotein5
  8121916                               RSPO3         -3.39         down         chr6    84870                       R-spondin3
  8129573                               MOXD1         -3.49         down         chr6    26002                       monooxygenase, DBH-like1
  7917561                               GBP4          -3.80         down         chr1    115361                      guanylatebindingprotein4
  7945680                               H19           -3.95         down         chr11   283120///100033819///6206   H19, imprinted maternally expressed transcript (non-protein coding) \|microRNA675\|ribosomalproteinS12
  8138289                               ETV1          -4.12         down         chr7    2115                        etsvariant1
  8131803                               IL6           -4.34         down         chr7    3569                        interleukin6
  8006433                               CCL2          -5.52         down         chr17   6347                        Chemokine (C-C motif) ligand2
  8150428                               SFRP1         -6.05         down         chr8    6422                        secretedfrizzled-relatedprotein1
  7933194                               CXCL12        -6.08         down         chr10   6387                        chemokine(C-X-C motif) ligand12
  **Endo I_E2 vs Veh**                                                                                               
  7965873                               IGF1          11.37         up           chr12   3479                        insulin-likegrowthfactor1(somatomedin C)
  7951165                               **PGR**       3.82          up           chr11   5241                        Progesterone receptor
  8117020                               MYLIP         3.34          up           chr6    29116                       Myosin regulatory light chain interacting protein
  8145766                               NRG1          2.94          up           chr8    3084                        neuregulin1
  8111490                               PRLR          2.82          up           chr5    5618                        Prolactin receptor
  8102950                               INPP4B        2.77          up           chr4    8821                        inositolpolyphosphate-4-phosphatase, type II,105kDa
  7942674                               TSKU          2.67          up           chr11   25987                       tsukushi, small leucine rich proteoglycan
  8043995                               IL1R1         2.55          up           chr2    3554                        interleukin1receptor, type I
  8088560                               ADAMTS9       2.45          up           chr3    56999                       ADAMmetallopeptidasewiththrombospondintype1motif,9
  8106516                               JMY           2.26          up           chr5    133746                      Junction mediating and regulatory protein, p53 cofactor
  8135069                               SERPINE1      -1.61         down         chr7    5054                        Serpin peptidase inhibitor, clade E (nexin,plasminogenactivatorinhibitortype1),member1
  7902565                               LPHN2         -1.66         down         chr1    23266///101927458           latrophilin2\|uncharacterizedLOC101927458
  7921916                               RGS5          -1.74         down         chr1    8490                        regulatorofG-proteinsignaling5
  7909503                               SERTAD4       -1.74         down         chr1    56256                       SERTAdomaincontaining4
  7968417                               FRY           -1.75         down         chr13   10129                       Furry homolog(Drosophila)
  7922343                               TNFSF4        -1.79         down         chr1    7292                        Tumor necrosis factor(ligand)superfamily,member4
  8006433                               CCL2          -1.90         down         chr17   6347                        chemokine(C-C motif) ligand2
  7906919                               RGS4          -2.02         down         chr1    5999                        regulatorofG-proteinsignaling4
  8021081                               SLC14A1       -2.37         down         chr18   6563                        solutecarrierfamily14(urea transporter), member1(Kidd blood group)
  7922337                               TNFSF18       -2.53         down         chr1    8995                        Tumor necrosis factor(ligand) superfamily, member18
  **Endo I_P4 vs Veh (All DE loci)**                                                                                 
  7964834                               CPM           2.06          up           chr12   1368                        Carboxypeptidase M
  8089145                               ABI3BP        1.90          up           chr3    25890                       ABI family, member3(NESH) binding protein
  8043995                               IL1R1         1.89          up           chr2    3554                        interleukin1receptor, type I
  8157524                               TLR4          1.88          up           chr9    7099                        toll-likereceptor4
  8101659                               SPARCL1       1.83          up           chr4    8404                        SPARC-like1(hevin)
  7907271                               FMO2          1.83          up           chr1    2327                        flavincontainingmonooxygenase2(non-functional)
  7933204                               C10orf10      1.65          up           chr10   11067                       chromosome10openreadingframe10
  7965873                               IGF1          1.65          up           chr12   3479                        insulin-likegrowthfactor1(somatomedin C)
  8122660                               UST           1.59          up           chr6    10090                       uronyl-2-sulfotransferase
  8052355                               EFEMP1        1.55          up           chr2    2202                        EGFcontainingfibulin-likeextracellularmatrixprotein1
  7969861                               ITGBL1        1.51          up           chr13   9358                        integrin, beta-like1(with EGF-like repeat domains)
  8100154                               CORIN         1.50          up           chr4    10699                       corin, serine peptidase
  7922337                               TNFSF18       -1.56         down         chr1    8995                        Tumor necrosis factor (ligand)superfamily, member18
  **Endo I_E2+P4 vs Veh**                                                                                            
  8101659                               SPARCL1       23.12         up           chr4    8404                        SPARC-like1(hevin)
  7965873                               IGF1          12.49         up           chr12   3479                        insulin-likegrowthfactor1(somatomedin C)
  8089145                               ABI3BP        10.15         up           chr3    25890                       ABI family, member3 (NESH) binding protein
  8155864                               RORB          8.92          up           chr9    6096                        RAR-related orphan receptor B
  8147030                               STMN2         7.62          up           chr8    11075                       stathmin2
  8043995                               IL1R1         6.73          up           chr2    3554                        interleukin1receptor, type I
  8125919                               FKBP5         5.05          up           chr6    2289                        FK506bindingprotein5
  7977933                               SLC7A8        4.04          up           chr14   23428                       solutecarrierfamily7(amino acid transporter light chain, L system), member 8
  8122099                               ENPP1         4.04          up           chr6    5167                        Ectonucleotide pyrophosphatase/phosphodiesterase1
  7964834                               CPM           3.96          up           chr12   1368                        Carboxypeptidase M
  8138289                               ETV1          -2.32         down         chr7    2115                        etsvariant1
  7921916                               RGS5          -2.34         down         chr1    8490                        regulatorofG-proteinsignaling5
  8081001                               ROBO2         -2.34         down         chr3    6092                        roundabout,axonguidancereceptor,homolog2(Drosophila)
  8136248                               MEST          -2.44         down         chr7    4232                        Mesoderm specific transcript
  7922343                               TNFSF4        -2.51         down         chr1    7292                        Tumor necrosis factor (ligand)superfamily, member 4
  7906919                               RGS4          -2.76         down         chr1    5999                        regulatorofG-proteinsignaling4
  8006433                               CCL2          -3.14         down         chr17   6347                        chemokine(C-C motif) ligand 2
  7922337                               TNFSF18       -3.29         down         chr1    8995                        Tumor necrosis factor (ligand) superfamily, member 18
  8021081                               SLC14A1       -3.33         down         chr18   6563                        solutecarrierfamily14(urea transporter), member 1(Kidd blood group)
  7945680                               H19           -3.62         down         chr11   283120///100033819///6206   H19,imprintedmaternallyexpressedtranscript(non-proteincoding)\|microRNA675\|ribosomalproteinS12
  **Endo IV_E2 vs Veh**                                                                                              
  7965873                               IGF1          12.71         up           chr12   3479                        insulin-likegrowthfactor1(somatomedin C)
  7951165                               **PGR**       5.19          up           chr11   5241                        Progesterone receptor
  8117020                               MYLIP         4.13          up           chr6    29116                       Myosin regulatory light chain interacting protein
  8111490                               PRLR          3.44          up           chr5    5618                        Prolactin receptor
  8102950                               INPP4B        2.88          up           chr4    8821                        inositolpolyphosphate-4-phosphatase, typeII,105kDa
  8040292                               GREB1         2.77          up           chr2    9687                        growthregulationbyestrogeninbreastcancer1
  8107823                               ADAMTS19      2.71          up           chr5    171019                      ADAMmetallopeptidasewiththrombospondintype1motif,19
  8088560                               ADAMTS9       2.51          up           chr3    56999                       ADAMmetallopeptidasewiththrombospondintype1motif,9
  8145361                               NEFM          2.48          up           chr8    4741                        neurofilament, medium polypeptide
  8106516                               JMY           2.43          up           chr5    133746                      Junction mediating and regulatory protein, p53 cofactor
  7920123                               S100A10       -1.94         down         chr1    6281                        S100calciumbindingproteinA10
  8131803                               IL6           -2.03         down         chr7    3569                        interleukin6
  8135218                               LRRC17        -2.11         down         chr7    10234                       leucinerichrepeatcontaining17
  7906919                               RGS4          -2.15         down         chr1    5999                        regulatorofG-proteinsignaling4
  7921916                               RGS5          -2.15         down         chr1    8490                        regulatorofG-proteinsignaling5
  7997139                               CALB2         -2.20         down         chr16   794                         calbindin2
  8021081                               SLC14A1       -2.23         down         chr18   6563                        solutecarrierfamily14(urea transporter), member 1(Kidd blood group)
  7922343                               TNFSF4        -2.51         down         chr1    7292                        Tumor necrosis factor (ligand) superfamily, member4
  7922337                               TNFSF18       -2.58         down         chr1    8995                        Tumor necrosis factor(ligand) superfamily, member 18
  8006433                               CCL2          -3.30         down         chr17   6347                        chemokine(C-C motif) ligand 2
  **Endo IV_P4 vs Veh (All DE loci)**                                                                                
  7907271                               FMO2          1.99          up           chr1    2327                        flavincontainingmonooxygenase2(non-functional)
  7908459                               CFH           1.93          up           chr1    3075                        Complement factor H
  7965873                               IGF1          1.85          up           chr12   3479                        insulin-likegrowthfactor1(somatomedin C)
  8043995                               IL1R1         1.82          up           chr2    3554                        interleukin1receptor, type I
  8157524                               TLR4          1.61          up           chr9    7099                        toll-likereceptor4
  7961514                               MGP           1.59          up           chr12   4256                        Matrix Gla protein
  8089145                               ABI3BP        1.58          up           chr3    25890                       ABI family, member3 (NESH)binding protein
  7933204                               C10orf10      1.58          up           chr10   11067                       chromosome10openreadingframe10
  8101659                               SPARCL1       1.51          up           chr4    8404                        SPARC-like1(hevin)
  8111490                               PRLR          1.50          up           chr5    5618                        Prolactin receptor
  8111941                               HMGCS1        -1.49         down         chr5    3157                        3-hydroxy-3-methylglutaryl-CoAsynthase1(soluble)
  **Endo IV_E2+P4 vs Veh**                                                                                           
  8101659                               SPARCL1       29.40         up           chr4    8404                        SPARC-like1(hevin)
  8089145                               ABI3BP        17.62         up           chr3    25890                       ABI family, member3 (NESH)binding protein
  7965873                               IGF1          17.30         up           chr12   3479                        insulin-likegrowthfactor1(somatomedin C)
  8122099                               ENPP1         10.98         up           chr6    5167                        Ectonucleotide pyrophosphatase/phosphodiesterase1
  8155864                               RORB          10.33         up           chr9    6096                        RAR-related orphan receptor B
  7977933                               SLC7A8        8.57          up           chr14   23428                       solutecarrierfamily7(amino acid transporter light chain, L system), member8
  8043995                               IL1R1         8.54          up           chr2    3554                        interleukin1receptor, type I
  7908459                               CFH           6.96          up           chr1    3075                        Complement factor H
  8138231                               THSD7A        6.18          up           chr7    221981                      thrombospondin, type I, domaincontaining7A
  8125919                               FKBP5         6.12          up           chr6    2289                        FK506bindingprotein5
  7997139                               CALB2         -3.00         down         chr16   794                         calbindin2
  8150428                               SFRP1         -3.12         down         chr8    6422                        secretedfrizzled-relatedprotein1
  7922337                               TNFSF18       -3.26         down         chr1    8995                        Tumor necrosis factor (ligand) superfamily, member 18
  7917561                               GBP4          -3.27         down         chr1    115361                      guanylatebindingprotein4
  8055323                               NCKAP5        -3.36         down         chr2    344148                      NCK-associatedprotein5
  8138289                               ETV1          -3.59         down         chr7    2115                        etsvariant1
  8021081                               SLC14A1       -3.81         down         chr18   6563                        solutecarrierfamily14 (urea transporter), member1(Kidd blood group)
  7922343                               TNFSF4        -4.00         down         chr1    7292                        Tumor necrosis factor (ligand) superfamily, member4
  7906919                               RGS4          -4.21         down         chr1    5999                        Regulator of G-proteinsignaling4
  8006433                               CCL2          -6.47         down         chr17   6347                        Chemokine (C-C motif)ligand2

E~2~+P~4~ induced the largest and P~4~ the smallest changes in gene expression. Almost all the genes differentially induced by P~4~ were shared with E~2~+P~4~ and some were shared with the E~2~ treatment. Notably, half of the E~2~-induced and the majority of E~2~+P~4~ induced differentially expressed genes were unique. However, in commonly up-regulated genes between E~2~ and E~2~+P~4~, the variable fold changes indicate inhibitory or stimulatory effects when E~2~ is combined with P~4~. For example, *PGR* is upregulated by both E~2~ and E~2~+P~4~ (FC = 4.5 vs 1.7, respectively), indicating that the addition of P~4~ limited up-regulation of *PGR* compared to E~2~ alone. Among other up-regulated gene in common in E~2~, P~4~, E~2~+P~4~, are *IGF1* and *SPARCL1* with known roles in endometrial biology. But, the FCs were different (*IGF1*: E~2~ = 21.5, P~4~ = 4.6, E~2~+P~4~ = 13.6; *SPARCL1*: E~2~ = 4.6, P~4~ = 13.2; E~2~+P~4~ = 53.1) indicating potentially different mechanisms for up- or down-regulation and for different genes, potentially affected by genomic location and other regulatory factors, modifiers and gene/region-specific mechanisms involved in hormone-induced gene expression regulation.

### Pathways and biofunctions {#sec006}

E~2~ increased tissue and cellular development, growth and maintenance, and downregulated cell-to-cell signaling, immune cell trafficking, inflammatory response, apoptosis and cellular migration (**[S5 Table](#pgen.1008601.s008){ref-type="supplementary-material"}**). P~4~ elicited down-regulation of cellular regeneration and proliferation and cell-cell signaling and adhesion. E~2~+P~4~ upregulated cell death and molecular transport and downregulated cell growth and proliferation, carbohydrate metabolism and molecular transport. The genes commonly upregulated by E~2~, P~4~, E~2~+P~4~ involved catalytic activity, receptor and signal transduction, binding, transporter and structural molecule activity. The main biofunctions of differentially expressed genes that were shared with differentially methylated loci involved cell membrane and signaling in response to E~2~.

Association of gene expression with DNA methylation {#sec007}
---------------------------------------------------

Hormonally-induced differentially methylated CpG sites were assessed for association with differential gene expression for each corresponding locus, noting that not all transcribed loci are included in both platforms and many intergenic regions in DNA methylation platform were not represented on the gene expression array used in this study. Only loci with a strong positive or negative association (by Spearman rho, and corrected p\<0.05, see [Methods](#sec026){ref-type="sec"}) were considered. There was a large number of functional gene clusters with strong association of DNA methylation and gene expression for E~2~ in eSF~normal~ (**[Table 5](#pgen.1008601.t005){ref-type="table"}**), which was not observed for P~4~ or E~2~+P~4~ treatments.

Effects of Ovarian Steroid Hormones in *Endometrium of Women with Endometriosis* {#sec008}
--------------------------------------------------------------------------------

We next aimed to determine the effect of hormones on the endometrium of endometriosis patient, known to have abnormal P~4~ response. We applied strict criteria using eSF from patients with only endometriosis and no other uterine, pelvic or gynecologic disorders and those that show P~4~-resistance confirmed by microscopy and IGFBP1 assay (**[S1 Fig](#pgen.1008601.s001){ref-type="supplementary-material"}**). Furthermore, to understand the effect of disease stage on the hormone-epigenome interplay, we used early (stage I) and late stage (stage IV) disease. Similar to normal, E~2~ induced the most and P~4~ the least DNA methylation changes in eSF~stage-I~ and eSF~stage-IV~ (**[Fig 2A and 2B](#pgen.1008601.g002){ref-type="fig"}, [S6](#pgen.1008601.s009){ref-type="supplementary-material"} and [S7](#pgen.1008601.s010){ref-type="supplementary-material"} Tables**, respectively). But, in eSF~endo~, the extent of E~2~-induced changes was less than in eSF~normal~ specifically in eSF~stage-IV~ (418 CpG sites) exhibiting significantly less methylation alterations compared to eSF~normal~ and eSF~stage-I~ (2047 and 1633 CpG sites, respectively) (**[Fig 2B](#pgen.1008601.g002){ref-type="fig"})**. Opposite to that of eSF~normal~ the majority of changes in both stages were gain of methylation (**[Fig 2A](#pgen.1008601.g002){ref-type="fig"}** heatmap). The extent of E~2~-induced differentially methylated loci differed considerably between the two stages (**[Fig 2A and 2B](#pgen.1008601.g002){ref-type="fig"}**): stage I showed extensive changes induced by E~2~, much reduced in stage IV. The considerable difference in the extent of E~2~- induced methylation in eSF~stage-IV~ and in the gain/loss pattern (**[Fig 2A and 2B](#pgen.1008601.g002){ref-type="fig"}**), indicate an aberrant response to E~2~ in both stages of disease and more extensively in stage IV, not previously reported. Progesterone, similar to eSF~normal~ induced the least DNA methylome alterations in both eSF~stage-I~ and eSF~stage-IV~ despite the difference in the robust decidualization response to P~4~ in eSF~normal~ and the refractory decidualization response to P~4~ in eSF~endo~ (**[S1 Fig](#pgen.1008601.s001){ref-type="supplementary-material"})**. While P~4~ induced similar numbers of loss and gain of methylation in eSF~normal~ in eSF~stage-I~ there was more loss than gain of methylation and in eSF~stage-IV~ more gain than loss of methylation. Interestingly, despite complete lack of decidualization, eSF~stage-I~ exhibited more E~2~+P~4~-induced differentially methylated loci versus eSF~normal~, and in both disease stages there was more loss than gain of methylation (**[Fig 2A and 2B](#pgen.1008601.g002){ref-type="fig"}**). eSF~stage-IV~ showed the fewest methylome changes in all three hormone treatments, suggesting extensive aberrancies in hormone-methylome interactions in late stage disease. Particularly important is the novel observation of an aberrant response to E~2~ and not just to P~4~ and E~2~+P~4,~ as previously believed \[[@pgen.1008601.ref024]\].

![Hormone induced differentially methylated CpG sites in [stage I eSF (Endo I) and stage IV eSF (Endo IV)]{.ul}.\
**2A.** Differentially methylated CpG sites induced by E~2~, P~4~ and E~2~+P~4~ versus vehicle. Heatmaps reflect the differential methylation of each sample in each hormone treatment versus its corresponding non-treated vehicle control (Δβ: Hormone treated minus vehicle control) (see [Fig 1A](#pgen.1008601.g001){ref-type="fig"} legend for details). **2B.** Number of differentially methylated CpG sites and in gain/loss of methylation for each hormone treatment in Endo I and Endo IV. **C.** Unique and common differentially methylated CpG sites for each hormone in Endo I (left) and Endo IV (right) indicating mostly unique loci for each hormone. 2**D**. Unique and common differentially methylated CpG sites across normal (NUP), Endo I and Endo IV, for each hormone: E~2~: left, P~4~: middle and E~2~+P~4~: right. **2E.** Enrichment of intergenic regions; Endo I, top and Endo IV bottom charts (see [Fig 1D](#pgen.1008601.g001){ref-type="fig"} legend for details). **2F.** Enrichment of enhancers for each hormone and based on loss or gain of methylation in Endo I (left panel) and Endo IV (right panel) (see [Fig 1E](#pgen.1008601.g001){ref-type="fig"} legend for details). **2G.** Genomic distribution of all differentially methylated CpG sites in each group (Endo I, left, Endo IV right panel) and by gain or loss of methylation (see [Fig 1F](#pgen.1008601.g001){ref-type="fig"} legend for details). **2H.** Distribution of differentially methylated CpGs by CpG islands (CGI), CGI north/south shores and shelves for Endo I (left) and Endo IV (right) based on gain or loss of methylation for all hormones. For details see [Fig 1G](#pgen.1008601.g001){ref-type="fig"} legend. N Shelf: North Shelf; S Shelf: South Shelf; N Shore: North Shore; S Shore: South Shore. Endo I: stage I; Endo IV: stage IV.](pgen.1008601.g002){#pgen.1008601.g002}

Differentially methylated loci were unique in response to different hormones in each disease stage and between the two stages. (**[Fig 2C](#pgen.1008601.g002){ref-type="fig"}**). As in normal, E~2~+P~4~ induced methylation were mostly unique and not a combination of the response to E~2~ or P~4~ individually (**[Fig 2C](#pgen.1008601.g002){ref-type="fig"}**), reaffirming that E~2~ and P~4~ interact differently with the epigenome when combined than when individually administered (**[Fig 2C](#pgen.1008601.g002){ref-type="fig"}, [S6](#pgen.1008601.s009){ref-type="supplementary-material"} and [S7](#pgen.1008601.s010){ref-type="supplementary-material"} Tables**). Moreover, the majority of loci differentially methylated in response to each specific hormone was also unique in eSF~normal~ vs eSF~stage-I~ vs eSF~stage-IV~ (**[Fig 2D](#pgen.1008601.g002){ref-type="fig"}**). These data suggest that the hormone-DNA methylome dynamics differ under normal and disease conditions, and furthermore that the stage of disease affect the hormone-methylome response.

Despite distinct profile differences with normal, hormone-induced differentially methylated CpGs for E~2~, P~4~ and E~2~+P~4~in both stages of eSF~endo~ were also statistically significantly enriched in intergenic regions (**[Fig 2E](#pgen.1008601.g002){ref-type="fig"}**) although the extent of this enrichment differed among hormone treatments, and between disease stages (**[Fig 2E](#pgen.1008601.g002){ref-type="fig"}**, **[S2 Fig](#pgen.1008601.s002){ref-type="supplementary-material"}** for gain/loss for each hormone**; [S2 Table](#pgen.1008601.s005){ref-type="supplementary-material"}**). Similar to normal and in both gain and loss of methylation, there was marked enrichment of enhancers, although the extent differed with specific hormone treatments and disease stage (**[Fig 2F](#pgen.1008601.g002){ref-type="fig"}**). In both E~2~ and P~4~ treatment, eSF~normal~ involved more enhancers than eSF~stage-I~ and eSF~stage-IV~, but E~2~+P~4~ treatment induced involvement of more enhancers in eSF~stage-IV~, particularly in loss of methylation with nearly 50% of CpGs associated with enhancers (**[Fig 2F](#pgen.1008601.g002){ref-type="fig"}**).

In eSF~stage-I~, the genomic distribution of loci with gain or loss of methylation differed from eSF~normal~ at 1^st^ exons, gene bodies, and 3'UTRs. In eSF~stage-IV~ the genomic distribution was mostly similar in gain and loss of methylation. These differed at 5'UTRs, gene bodies and 3'UTRs compared to eSF~normal~ and at 5'UTRs and 1^st^ exons compared to eSF~stage-I~ (**[Fig 2G](#pgen.1008601.g002){ref-type="fig"}**). Overall, these data demonstrate that: hormone treatments regardless of disease and its stage affected CpG sites more at the 3'UTR and intergenic regions and much less at proximal promoters/TSS; genomic locations of CpG sites differentially methylated in response to hormones differed based on loss/gain of methylation; while decreased proximal promoter (TSS200) involvement and increased intergenic region involvement were common in eSF~normal,~ eSF~stage-I~ and eSF~stage-IV~. Low involvement of promoters/TSS and increased involvement of 3'UTR and intergenic regions were remarkable, considering vast differences in patterns, profiles and loci differentially methylated in eSF under the different hormonal treatments and in normal versus disease. These observations underscore key roles for genomic locations and potentially chromatin configurations further directing hormonal effects.

*CpG islands (CGI)*, *CGI shores and shelves*. There was low involvement of CGIs and CGI shelves and shores in both disease stages **[Fig 2H](#pgen.1008601.g002){ref-type="fig"}** (and **[S3 Table](#pgen.1008601.s006){ref-type="supplementary-material"}**), similar to normal. But, in both disease stages loss of methylation involved more CGIs than gain of methylation.

Pathways and biofunctions associated with differentially methylated loci {#sec009}
------------------------------------------------------------------------

Interestingly, hormone treatments significantly enriched more pathways in eSF~stage-I~ and eSF~stage-IV~ versus eSF~normal~ (**[Table 1](#pgen.1008601.t001){ref-type="table"}**) (**[S1 Data](#pgen.1008601.s022){ref-type="supplementary-material"}** shows important pathways affected by each hormone in each eSF group and marking differentially methylated genes in those pathways*)*. Thus, while there were fewer loci in eSF~stage-I~ and eSF~stage-IV~ compared to eSF~normal~, more specific pathways were affected; whereas, with eSF~normal~ hormone effects did not particularly affect specific canonical pathways and likely involved broader targets across the genome. E~2~ affected pathways in eSF~stage-I~ involved endometrial function/dysfunction and endometriosis (e.g. MAPK, PI3K-Akt, ErbB signaling, focal adhesion, gap junctions, among others (**[Table 1](#pgen.1008601.t001){ref-type="table"}**)). E~2~ elicited pathways in eSF~stage-IV~ associated with proteoglycans and estrogen, ErbB, Ras, GnRH, and FoxO signaling (**[Table 1](#pgen.1008601.t001){ref-type="table"}**)--all relevant to endometriosis pathophysiology \[[@pgen.1008601.ref008],[@pgen.1008601.ref014]\]. While P~4~ did not significantly enrich specific pathways in eSF~normal,~ indicating a more genome-wide effect instead of limited effect at specific canonical pathways, several statistically significant pathways were enriched in eSF~stage-I~ and even more in eSF~stage-IV~. These data suggest an aberrant response to P~4~ in eSF from women with disease, which is enhanced in stage IV (**[Table 1](#pgen.1008601.t001){ref-type="table"}**) involving specific pathways including estrogen, MAPK and ErbB signaling, confirming pathways associated with transcriptomic data \[[@pgen.1008601.ref019],[@pgen.1008601.ref020]\]. Similarly, in response to E~2~+P~4~, there were more enriched pathways in eSF~endo~ than in eSF~normal~ relevant to endometrial function (adhesion, and disease/cancer (**[Table 1](#pgen.1008601.t001){ref-type="table"}**)).

Gene functional enrichments in eSF~normal~, eSF~stage-I~ and eSF~stage-IV~ for each hormone treatment are shown in **[Table 2](#pgen.1008601.t002){ref-type="table"}.** While there was little overlap in genes or functional clusters in eSF~endo~ compared to eSF~normal~, the greatest number of genes in the same functional cluster in all eSF groups induced by E~2~ involved those with signal peptide, membrane, and glycoprotein functions. eSF~stage-I~ had more gene functional clusters with specific functions in all hormone treatments compared to eSF~stage-IV~ or eSF~normal~. eSF~stage-IV~ had the fewest functional clusters in all treatments compared to eSF~stage-I~ and eSF~normal~, and the genes affected specific pathways involved in endometriosis and cancer as observed in the pathway analysis (above). Importantly, P~4~ treatment affected specific gene functions in disease (adhesion, synapse, cell junction, cadherins), different from eSF~normal~. E~2~+P~4~ elicited, only in eSF~stage-I~, several distinct functional clusters with specific functions in endometrial biology and endometriosis, including EGF/EGF-like genes, ECM receptor interaction, focal adhesion, PI3K-Akt pathway, synapse, cell junctions, spectrins and others. The most enriched cluster elicited by E~2~+P~4~ in eSF~stage-IV~ included fibronectins (large glycoproteins in ECM that bind integrins and other matrix components with major roles in cell adhesion, growth, migration differentiation, fibrosis and cancer).

Functional enrichment differences did not show a gradual change from eSF~normal~ to eSF~stage-I~ and then to eSF~stage-IV~, rather showed distinct enrichments, suggesting inherent differences between disease stages. These data support that stage I and stage IV belong to distinct disease subtypes.

Aberrant hormone-induced methylation in eSF~endo~ are due to pre-existing methylation abnormalities {#sec010}
---------------------------------------------------------------------------------------------------

As patterns, profiles, pathways and gene functions differed in responses of eSF~stage-I,~ and eSF~stage-IV~ to E~2~, P~4~ and E~2~+P~4~ in comparison to those of eSF~normal,~ the question arose whether these could be due, in part, to aberrant DNA methylation signatures present *prior to* hormone treatment (referred to "pre-existing differences" herein). The DNA methylation status of untreated (vehicle) eSF~endo~ from women with endometriosis were assessed for loci with aberrant methylation changes in response to each hormone, compared to eSF~normal~ and whether they differed from untreated (vehicle) eSF~normal~ (see [Methods](#sec026){ref-type="sec"}). Numerous aberrantly differentially methylated loci in disease were found to be due to *pre-existing* DNA methylation differences across the genome (**[S3 Fig](#pgen.1008601.s003){ref-type="supplementary-material"}**), including up to 53% of aberrant E~2~+P~4~ loss of methylation in eSF~stage-IV~, showing an aberrant methylation pattern from that of the untreated normal eSF, further resulting in aberrant response to hormone treatments. These data are supported by previous gene expression analysis of eSF~normal~ and eSF~endo~ at t = 0 in culture \[[@pgen.1008601.ref019]\], demonstrating intrinsic and pre-existing abnormalities in the eSF~endo~ cells, although unclear whether these aberrancies are due to disease or are contributing to its progression/pathogenesis.

Changes in gene expression in response to hormones {#sec011}
--------------------------------------------------

As in eSF~normal~, transcriptomic profiles were determined for both stages of disease for each hormone (versus control). Whether these responses were abnormal was investigated compared to normal. In eSF~endo~, all treatments resulted in fewer differentially expressed genes versus eSF~normal~ (**[Table 3](#pgen.1008601.t003){ref-type="table"}, [S8](#pgen.1008601.s011){ref-type="supplementary-material"} and [S9](#pgen.1008601.s012){ref-type="supplementary-material"} Tables)**. P~4~ alone induced the fewest differentially expressed genes in eSF~stage-I,~ and eSF~stage-IV~, consistent with the DNA methylation changes, an aberrant response to P~4~ and abnormal decidualization in eSF from women with endometriosis (**[Fig 2A](#pgen.1008601.g002){ref-type="fig"}**) \[[@pgen.1008601.ref018],[@pgen.1008601.ref019]\]. In general, genes differentially expressed in response to each hormonal treatment were different in each disease stage versus normal, although some were in common (**[Table 4](#pgen.1008601.t004){ref-type="table"}**). Of interest to endometrial function and in disease, *PGR* was also upregulated in response to E~2~ in eSF~stage-I,~ and eSF~stage-IV~ similar to eSF~normal~ (**[Table 4](#pgen.1008601.t004){ref-type="table"}**) and was also among the top up-regulated genes in all groups despite the aberrant and very limited P~4~ response observed in the DNA methylation, gene expression and IGFBP1 production in eSF from women with disease (**[Table 3](#pgen.1008601.t003){ref-type="table"}, [S1 Fig](#pgen.1008601.s001){ref-type="supplementary-material"}**). E~2~, P~4~ and E~2~+P~4~ up-regulated *IGF1* and IL1R1 in all eSF and *SPARCL1* was up-regulated in all E~2~+P~4~ treated eSF (**[Table 4](#pgen.1008601.t004){ref-type="table"}, [S10 Table](#pgen.1008601.s013){ref-type="supplementary-material"}** (full list and Venn diagrams of unique and common genes within each group and each hormone treatment across groups)). Gene expression profiles in response to hormones, similar to the DNA methylome, demonstrated distinct and aberrant molecular signatures in eSF~stage-I~ versus eSF~stage-IV~ and compared to eSF~normal~. Moreover, these were not limited to P~4~ and E~2~+P~4~ treatments and, importantly, included an abnormal response of eSF~stage-I~ and eSF~stage-IV~ to E~2.~

10.1371/journal.pgen.1008601.t004

###### Differentially expressed loci common in each hormone treatment across normal (NUP), stage I (Endo I) and stage IV (Endo IV).
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  E2-induced upregulated loci common in NUP_Endo I\_ Endo IV                           E2-induced downregulated loci common in NUP_Endo I\_ Endo IV   P4-induced upregulated loci common in NUP_Endo I\_ Endo IV   E2+P4-induced upregulated loci common in NUP_Endo I_Endo IV   E2+P4-induced downregulated loci common in NUP_Endo I\_ Endo IV   
  ------------------------------------------------------------------------------------ -------------------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------- ----------------------------------------------------------------- --------------------------------------------------
  **IGF1**[\*](#t004fn001){ref-type="table-fn"}[\^](#t004fn002){ref-type="table-fn"}   NUAK1                                                          ABI3BP                                                       SPARCL1                                                       SLC29A1                                                           LIMCH1
  GREB1[\^](#t004fn002){ref-type="table-fn"}                                           NCAM1                                                          SPARCL1                                                      ABI3BP                                                        ZBTB16                                                            ROBO2
  PGR[\^](#t004fn002){ref-type="table-fn"}                                             SERPINE1                                                       **IGF1**[\*](#t004fn001){ref-type="table-fn"}                RORB                                                          RAB31[\^](#t004fn002){ref-type="table-fn"}                        KRT18
  LCP1[\^](#t004fn002){ref-type="table-fn"}                                            TNFSF18                                                        **IL1R1**[\*](#t004fn001){ref-type="table-fn"}               GREB1[\^](#t004fn002){ref-type="table-fn"}                    KLF6                                                              PIK3R3
  ADAMTS9                                                                              SLC14A1U[\*\*\*](#t004fn004){ref-type="table-fn"}              C10orf10                                                     SLC7A8                                                        PEMT                                                              PTCHD4
  ADAMTS19                                                                             FLT1                                                           TLR4                                                         **IGF1**[\^](#t004fn002){ref-type="table-fn"}                 RGS9                                                              RASSF2
  IL17RB                                                                               TNFSF4                                                                                                                      THSD7A                                                        PCBP3                                                             GALNT5
  SNCA[\^](#t004fn002){ref-type="table-fn"}                                            MEST[\*\*\*](#t004fn004){ref-type="table-fn"}                                                                               LCP1[\^](#t004fn002){ref-type="table-fn"}                     ITPR1                                                             FRY[\*\*\*](#t004fn004){ref-type="table-fn"}
  ISOC1                                                                                LMO7[\*\*\*](#t004fn004){ref-type="table-fn"}                                                                               FBXO32                                                        AHNAK2                                                            RNA5SP104
  MYLIP                                                                                EDNRA[\*\*\*](#t004fn004){ref-type="table-fn"}                                                                              MAOB                                                          MAP3K4                                                            FAM46C
  TSKU[\^](#t004fn002){ref-type="table-fn"}                                            RGS5[\*\*\*](#t004fn004){ref-type="table-fn"}                                                                               FKBP5                                                         SOD2                                                              TYMS
  NRG1[\^](#t004fn002){ref-type="table-fn"}                                            FRY[\*\*\*](#t004fn004){ref-type="table-fn"}                                                                                ENPP1                                                         CNTN3                                                             LYPD1
  SEMA6A                                                                               SERTAD4[\*\*\*](#t004fn004){ref-type="table-fn"}                                                                            CRISPLD2                                                      ADAMTS1                                                           SLC14A1[\*\*\*](#t004fn004){ref-type="table-fn"}
  GUCY1A2                                                                              CCL2[\*\*\*](#t004fn004){ref-type="table-fn"}                                                                               ULK4                                                          SPTSSA                                                            ARHGAP18
  PRLR[\^](#t004fn002){ref-type="table-fn"}                                            RGS4[\*\*\*](#t004fn004){ref-type="table-fn"}                                                                               **IL1R1**[\^](#t004fn002){ref-type="table-fn"}                SORBS1                                                            PLK2
  PRICKLE2[\^](#t004fn002){ref-type="table-fn"}                                                                                                                                                                    IMPA2                                                         TSC22D3                                                           ENC1
  JMY                                                                                                                                                                                                              MUM1L1                                                        LAMA3                                                             SULF1
  MIR503                                                                                                                                                                                                           GPX3                                                          ITGBL1                                                            MYO1B
  KLF4                                                                                                                                                                                                             STMN2                                                         SYTL4                                                             SYTL5
  IL1R1[\*](#t004fn001){ref-type="table-fn"}[\^](#t004fn002){ref-type="table-fn"}                                                                                                                                  CRYAB                                                         PMP22                                                             ATP8B1
  AFAP1L2                                                                                                                                                                                                          SPSB1                                                         SH3PXD2B                                                          AMIGO2
  ASPN[\^](#t004fn002){ref-type="table-fn"}                                                                                                                                                                        TMEM37                                                        MFGE8                                                             UGCG
  INPP4B                                                                                                                                                                                                           CPM                                                           PIK3R1                                                            KRTAP1-5
  PXK                                                                                                                                                                                                              GALNT15                                                       NID1                                                              PLEKHG1
  TMEM120B                                                                                                                                                                                                         MYOCD                                                         EVA1C                                                             GPR39
  MIR503HG                                                                                                                                                                                                         ST6GALNAC2                                                    APOD                                                              LOXL4[\*\*](#t004fn003){ref-type="table-fn"}
  CPXM1                                                                                                                                                                                                            THBD                                                          ABCC9                                                             ATP2B1
  LIN7A                                                                                                                                                                                                            FAM134B                                                       CD151                                                             TMEM130
  NEFM                                                                                                                                                                                                             LPAR1                                                         EPS8                                                              MGAT5
  BMP2                                                                                                                                                                                                             GPRC5B                                                        SEPP1                                                             GLT8D2
  SLC35F6[\^](#t004fn002){ref-type="table-fn"}                                                                                                                                                                     PRLR[\^](#t004fn002){ref-type="table-fn"}                     LAMA2                                                             CCDC14
  FAM102A                                                                                                                                                                                                          CERS6                                                         FOXO1                                                             MEST[\*\*\*](#t004fn004){ref-type="table-fn"}
  CPZ                                                                                                                                                                                                              MGST1                                                         ARHGAP20                                                          PPP1R3C
  OSBPL3                                                                                                                                                                                                           ABHD5                                                         PPAP2B                                                            RARRES2
  SNCAIP                                                                                                                                                                                                           C10orf10                                                      NRG1[\^](#t004fn002){ref-type="table-fn"}                         RASGRF2
  LOXL4[\*\*](#t004fn003){ref-type="table-fn"}                                                                                                                                                                     CD68                                                          TXNIP                                                             PGRMC1
  RNU2-6P                                                                                                                                                                                                          CXCR4                                                         RAP2A                                                             ACKR4
  ACER3                                                                                                                                                                                                            GLULP4                                                        FBLN2                                                             LMO7[\*\*\*](#t004fn004){ref-type="table-fn"}
  RAB31[\^](#t004fn002){ref-type="table-fn"}                                                                                                                                                                       EFEMP1                                                        ETS2                                                              GBP2
  PAPSS2                                                                                                                                                                                                           SESTD1                                                        TMOD1[\^](#t004fn002){ref-type="table-fn"}                        ARHGAP29
  ASCC3                                                                                                                                                                                                            NLGN4X                                                        HAND2-AS1                                                         SERTAD4[\*\*\*](#t004fn004){ref-type="table-fn"}
  TMOD1[\^](#t004fn002){ref-type="table-fn"}                                                                                                                                                                       PRUNE2                                                        PTGER2                                                            CSRNP3
  C16orf45                                                                                                                                                                                                         OLFML2B                                                       LHFP                                                              GABRE
  CDH4                                                                                                                                                                                                             SLC40A1                                                       PPP1R14A                                                          FJX1
                                                                                                                                                                                                                   HAND2                                                         LAMB1                                                             RGS5[\*\*\*](#t004fn004){ref-type="table-fn"}
                                                                                                                                                                                                                   ADAMTS2                                                       TLR4                                                              FHOD3
                                                                                                                                                                                                                   TSKU[\^](#t004fn002){ref-type="table-fn"}                     LMCD1                                                             CD200
                                                                                                                                                                                                                   GLUL                                                          RAP1B                                                             TNFRSF19
                                                                                                                                                                                                                   ABLIM3                                                        CFH                                                               DUSP6
                                                                                                                                                                                                                   CORIN                                                         YBX3                                                              PTN
                                                                                                                                                                                                                   ACSL1                                                         PGR[\^](#t004fn002){ref-type="table-fn"}                          TGFBI
                                                                                                                                                                                                                   IRS2                                                          RPS6KA2                                                           KRT19
                                                                                                                                                                                                                   MEDAG                                                         SLC35F6[\^](#t004fn002){ref-type="table-fn"}                      F2RL2
                                                                                                                                                                                                                   HOMER1                                                        PPP1R3B                                                           DACH1
                                                                                                                                                                                                                   ADRA2C                                                        NPC1                                                              NCAM2
                                                                                                                                                                                                                   DPT                                                           PLIN2                                                             MXRA5
                                                                                                                                                                                                                   ASPN[\^](#t004fn002){ref-type="table-fn"}                     PRICKLE2[\^](#t004fn002){ref-type="table-fn"}                     RGS4[\*\*\*](#t004fn004){ref-type="table-fn"}
                                                                                                                                                                                                                   MOB3B                                                         HSPA2                                                             EDNRA[\*\*\*](#t004fn004){ref-type="table-fn"}
                                                                                                                                                                                                                   NFIL3                                                         DPP4                                                              NCKAP5
                                                                                                                                                                                                                   INSR                                                          ITGB1BP1                                                          MOXD1
                                                                                                                                                                                                                   ARRDC4                                                        PQLC3                                                             GBP4
                                                                                                                                                                                                                   DKK1                                                          APCDD1                                                            H19
                                                                                                                                                                                                                   SNCA[\^](#t004fn002){ref-type="table-fn"}                     ENDOD1                                                            ETV1
                                                                                                                                                                                                                   SRPX                                                          ANTXR2                                                            IL6
                                                                                                                                                                                                                   UST                                                           ANG                                                               CCL2[\*\*\*](#t004fn004){ref-type="table-fn"}
                                                                                                                                                                                                                   ELMO1                                                         GRIA1                                                             SFRP1

\* in both common E2 and common P4 up-regulated genes

\^ in both E2 and E2+P4 up-regulated; **BOLD,** in E2, P4 and E2+P4 common loci

\*\* Up regulated in E2 and down regulated in E2+P4

\*\*\* Down-regulated in E2 and E+P. *NOTE*: *There are no P4-induced downregulated loci in common in NUP*, *Endo I*, *Endo IV*.

Changes in gene expression in stage I disease {#sec012}
---------------------------------------------

In eSF~stage\ I~, similar to eSF~normal~, all hormone treatments resulted in more gene up-regulation than down-regulation, but unlike eSF~normal~, all hormones, including E~2~ affected fewer differentially expressed genes, with a marked minimal effect with P~4~ (**[S8 Table](#pgen.1008601.s011){ref-type="supplementary-material"}**, full gene list; **[S10 Table](#pgen.1008601.s013){ref-type="supplementary-material"}**, common genes and Venn diagrams). Also, in E~2~ and in E~2~+P~4~ half and the majority of the genes, respectively, were unique, but in P~4~, the majority of differentially expressed genes were in common with E~2~+P~4~. Note that the number of P~4~-induced differentially expressed genes were very limited in stage I, while the combination of E~2~+P~4~ in stage I disease resulted in more differentially expressed genes than with E~2~ or P~4~ treatments alone (**[S8 Table](#pgen.1008601.s011){ref-type="supplementary-material"}**). Similar to eSF~normal~, where addition of E~2~ minimally affected P~4~ target genes, E~2~ combined with P~4~ affected the target genes of E~2~ alone. While there were commonly upregulated P~4~ target genes eSF~stage\ I~ and eSF~normal~ including *IGF1*, *GREB1*, and *PGR*, *many key genes were missing in* eSF~stage\ I~, such as, *SPARCL1* which was upregulated in normal but not in stage I disease, further indicating an aberrant E~2~ response in disease.

Changes in gene expression in stage IV {#sec013}
--------------------------------------

Similar to eSF~stage\ I~ the number of differentially expressed genes in response to E~2~ as well as to P~4~ treatments were far fewer than what was observed in eSF~normal~ (**[S9 Table](#pgen.1008601.s012){ref-type="supplementary-material"}**, full gene list). Similar to eSF~normal~ and eSF~stage\ I~ there were more differentially expressed genes by E~2~+P~4~. Among commonly up-regulated E~2~+P~4~ induced eSF~stageIV~ and eSF~normal~ were *SPARCL1*, *IGF1*, and *LAMA3*. Among the 103 genes commonly down-regulated were *CCL2*, *RGS4*, *RGS5*, *IL-6*, *MEST*, *KRT19*, *KRT18 and H19*. The overlap in differential expression of specific up- and down-regulated genes with E~2~+P~4~ treatment of eSF from women with and without endometriosis is remarkable, since stage IV disease eSF cells did not decidualize and are not considered to be P~4~-responsive \[[@pgen.1008601.ref024],[@pgen.1008601.ref025]\].

Pathways and biofunctions {#sec014}
-------------------------

Pathways and biofunctions, derived from the gene expression data, underscored distinct differences between eSF~endo~ and eSF~normal~ and between stages of disease, similar to the DNA methylation data. In eSF~stage-I,~ with more limited E~2~ effects, pathways included activation of cellular proliferation and viability (**[S5 Table](#pgen.1008601.s008){ref-type="supplementary-material"}**), and eSF~stage-IV~ involved increased tissue and cellular development (as with eSF~normal~), proliferation, cell-cell signaling and adhesion (unlike eSF~normal~). Note that E~2~-induced biofunctions and pathways were different in eSF~stage-I~ and eSF~stage-IV~ and both differed from eSF~normal~ (**[S5 Table](#pgen.1008601.s008){ref-type="supplementary-material"}**), consistent with the DNA methylation data. There were no enriched pathways in eSF~stage-I~ and moderately enriched (Z score = 1.9) up-regulation of cell growth and proliferation in eSF~stage-IV~ in reponse to P4 (far fewer loci). Similar to eSF~normal~, carbohydrate metabolism and molecular transport was also seen in eSF~stage-I~ in response to E~2~+P~4~, which also showed up-regulation of cell invasion and viability. Importantly, E~2~+P~4~ increased cell survival, cell movement and invasion, cell-to-cell signaling and adhesion, and downregulated cellular proliferation and growth in eSF~stage-IV~. Genes involved in these pathways and their upstream regulators are shown in **[S5 Table](#pgen.1008601.s008){ref-type="supplementary-material"}**. Similar to normal, the main biofunctions of differentially expressed genes that were shared with differentially methylated loci involved cell membrane and signaling in response to E~2~ in eSF~stage-IV~.

Association of gene expression with DNA methylation {#sec015}
---------------------------------------------------

In loci with a strong positive or negative association of DNA methylation and gene expression (by Spearman rho, and corrected p\<0.05) distinct differences were found in eSF~stage-I~ and eSF~stage-IV~ and versus eSF~normal~ (full lists, **[S11](#pgen.1008601.s014){ref-type="supplementary-material"}--[S13](#pgen.1008601.s016){ref-type="supplementary-material"} Tables; [S14 Table](#pgen.1008601.s017){ref-type="supplementary-material"}** for unique and common loci between each group). Functional enrichment analyses revealed distinct differences in numbers and types of gene functional clusters in each stage of disease versus normal. While there was a large number of functional gene clusters with strong association for E~2~ in eSF~normal~ (**[Table 5](#pgen.1008601.t005){ref-type="table"}**), eSF~stage-I~ and eSF~stage-IV~ showed different and more limited functional clusters. This result further indicates that the E~2~ response is aberrant in eSF~endo~ compared to normal eSF.

10.1371/journal.pgen.1008601.t005

###### Functional enrichment cluster analysis for loci with strong association of differential methylation and gene expression changes in each hormone treatment in normal (NUP), stage I (Endo I) and stage IV (Endo IV) disease.
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  Enrichment score\>2 and P\<0.05        E~2~ vs. Veh                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     P~4~ vs. Veh                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    E~2~+P~4~ vs. Veh
  -------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NUP, pos/neg rho (gain and loss)       Cluster 1: Spectrins, Spectrin/alpha-actinin, Actinin-type, actin-binding, Calponin homology (CH) domain, Cell division and chromosome partitioning, DNA replication, recombination, and repair. Cluster 2: ATP-binding, Protein kinase-like domain, protein kinase activity, Nucleotide-binding, protein phosphorylation, intracellular signal transduction, Serine/threonine-protein kinase. Cluster 3: Pleckstrin homology-like domain, PH. Cluster 5: Metal-binding, Zinc, Zinc-finger, zinc ion binding. Cluster 6: Cell adhesion, Cadherins. Cluster 7: Biological rhythms, regulation of circadian rhythm, rhythmic process. Cluster 8: postsynaptic membrane, Cell junction, Synapse. Cluster 9: GTPase activator activity, Rho GTPase activation protein, regulation of small GTPase mediated signal transduction. Cluster 10: Fibronectins. Cluster 11: zinc finger region: ZZ-type.   Cluster 1: Dynein heavy chain/domain, microtubule motor activity. cluster 2; Zinc, zinc ion binding, Zinc-finger, Metal-binding.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                No functional cluster enrichment with significant p-value and enrichment score\>2.
  Endo I, pos/neg rho, (gain and loss)   Cluster1: cell adhesion, cadherins, calcium ion channel. Cluster 2: a number of Sushi domains. Cluster 3: SAM. Cluster 4: ATP-binding, nucleotide phosphate-binding region: ATP, Nucleotide-binding, Kinase.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     cluster 1: homophilic cell adhesion via plasma membrane adhesion molecules, Cadherins, Cell adhesion, calcium ion binding, CA. Cluster 2: Synapse, Cell junction, Postsynaptic cell membrane. Cluster 3: regulation of small GTPase mediated signal transduction, positive regulation of GTPase activity, Rho GTPase activation protein, signal transduction. Cluster 4: Sterile alpha motif domain (SAM). Cluster 5: regulation of small GTPase mediated signal transduction, Dbl homology (DH) domain, Rho guanyl-nucleotide exchange factor activity, Pleckstrin homology-like domain, positive regulation of apoptotic process, Src homology-3 domain, intracellular signal transduction.   Cluster 1: PDZ/PDZ domain. Cluster2: EGF, EGF-like, EGF-like calcium-binding, Laminin, Insulin-like growth factor binding protein, TB domain, Extracellular matrix, Secreted. Cluster 3: Calponin homology (CH) domain. Cluster 4: Cell junction, Synapse, Postsynaptic cell membrane, neuron projection.
  Endo IV, pos/neg rho (gain and loss)   Cluster 1: plasma membrane, topological domain: Extracellular, Glycoprotein, Signal, Disulfide bond, Transmembrane. Cluster 2: Neurexin/syndecan/glycophorin C, cell adhesion.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   No enrichment in functional clusters (total probes = 106) with our stat cut off, but some enrichment without ES\>2 include: cluster 1 at 1.69: Fibronectins, Laminin, cell adhesion, extracellular matrix, secreted. Cluster 2: 1.13: cell adhesion, glycoprotein, cell membrane, signal.                                                                                                                                                                                                                                                                                                                                                                                                       cluster 1: repeat I, II, III, IV (this includes these: calcium voltage-gated channel subunit alpha1 C(CACNA1C), calcium voltage-gated channel subunit alpha1 A(CACNA1A), integrin subunit beta like 1(ITGBL1). *(cluster 2: 1.8: Phosphotyrosine interaction domain. Cluster 3 (1.56):Pleckstrin homology-like domain. Cluster 4: (1.4): synapse, cell junction)*.

There were also multiple differences in response to P~4~, and E~2~+P~4~ among the eSF groups, further highlighting distinct molecular signatures in each disease stage. Importantly, eSF~stage-I~ showed distinct clusters in response to P~4~ and to E~2~+P~4,~ including functions characteristic of endometrial biology and endometriosis pathophysiology (**[Table 5](#pgen.1008601.t005){ref-type="table"}**).

While there were no statistically significantly enriched gene functional clusters in response to P4 in stage IV disease, a moderate enrichment of fibronectins, cell adhesion and secreted proteins were noted. These are consistent with the important role for cell adhesion in stage I and stage IV disease. In response to E~2~+P~4~, eSF~stage-IV~ showed enrichment of calcium channels and integrins. Together these data suggest that the responses to all hormone treatments are aberrant in eSF derived from women with stage I and stage IV disease and are specific to each stage, supporting distinct disease subtypes.

Comparison of *in vitro* versus *in vivo* data {#sec016}
----------------------------------------------

Herein, eSF hormone treatments *in vitro* were chosen to approximate the hormonal milieu *in vivo* (E~2~-dominant proliferative phase endometrium (PE) and E~2~+P~4~-dominant mid-secretory phase endometrium (MSE)). Comparing *in vitro* hormone eSF transcriptome data to corresponding phases in bulk endometrial tissue in normal versus disease \[[@pgen.1008601.ref026]\] and FACS-isolated eSF~endo~ and eSF~normal~ \[[@pgen.1008601.ref020]\] revealed great overlap of differentially expressed genes (**[Table 6](#pgen.1008601.t006){ref-type="table"}, [S15](#pgen.1008601.s018){ref-type="supplementary-material"} and [S16](#pgen.1008601.s019){ref-type="supplementary-material"} Tables**). GO functional analysis of genes differentially expressed in E~2~ treated eSF~stage-IV~ and PE tissue revealed many genes in common involved in regulation of cell migration and motility, proteolysis, negative regulation of cell death, regulation of fibroblast proliferation and others. Regulation of inflammatory response, cell migration/motility, transport, protein import to nucleus, signal transduction, wound healing, and epithelial development and others were noted in stage I (**[S15 Table](#pgen.1008601.s018){ref-type="supplementary-material"}**).

10.1371/journal.pgen.1008601.t006

###### Genes commonly regulated in eSF treated with E~2~ and E~2~+P~4~ and in whole endometrial tissue in PE and MSE or in FACS sorted eSF.
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  ----------------------------------------------------------------------------------------------------------------------- ------------------------------ ----------------------------------- ---------------------------------- -------------------------------------- ----------------------------------------------------------- -----------------------------------------------------------------------------------------------
  **eSF E**~**2**~ **treated in common with WHOLE Tissue PE in Disease vs. Control**                                                                                                                                                                                                                                               
  Gene Symbol                                                                                                             In Vitro array.Probe.Set. ID   FC (\[Endo IV-E\] vs \[NUP-E\])     FC (\[Endo I-E\] vs \[NUP-E\])     FC (\[PE.Endo\] vs \[PE.Control\])     Tissue array. Probe.Set.ID                                  Gene Title
  SPARCL1                                                                                                                 8101659                        -2.86                               -4.51                              -2.77                                  200795_at                                                   SPARC-like 1 (hevin)
  CXCL12                                                                                                                  7933194                        -2.79                               -2.02                              -2.20                                  203666_at                                                   chemokine (C-X-C motif) ligand 12
  GREB1                                                                                                                   8040292                        -2.77                               -3.49                              -1.66                                  205862_at                                                   growth regulation by estrogen in breast cancer 1
  IL1R1                                                                                                                   8043995                        -2.53                               -1.76                              -2.30                                  202948_at                                                   interleukin 1 receptor, type I
  COLEC12                                                                                                                 8021946                        -2.23                               -2.02                              -2.33                                  221019_s\_at                                                collectin sub-family member 12
  LCP1                                                                                                                    7971461                        -2.12                               -2.66                              -1.73                                  208885_at                                                   lymphocyte cytosolic protein 1 (L-plastin)
  FAM134B                                                                                                                 8111136                        -2.09                               -1.82                              -2.82                                  218532_s\_at                                                family with sequence similarity 134, member B
  IGF1                                                                                                                    7965873                        -2.07                               -2.76                              -2.68                                  209540_at                                                   insulin-like growth factor 1 (somatomedin C)
  ADAMTS9                                                                                                                 8088560                        -2.02                               -2.06                              -3.77                                  226814_at                                                   ADAM metallopeptidase with thrombospondin type 1 motif, 9
  SLC40A1                                                                                                                 8057677                        -2.01                               -2.25                              -1.98                                  223044_at                                                   solute carrier family 40 (iron-regulated transporter), member 1
  PDE7B                                                                                                                   8122222                        -1.97                               -2.00                              -2.44                                  230109_at                                                   phosphodiesterase 7B
  PLIN2                                                                                                                   8160297                        -1.94                               -1.65                              -2.18                                  209122_at                                                   perilipin 2
  IL17RB                                                                                                                  8080562                        -1.93                               -2.36                              -2.27                                  224156_x\_at                                                interleukin 17 receptor B
  SPTLC2                                                                                                                  7980438                        -1.91                               -1.72                              -5.38                                  203128_at                                                   serine palmitoyl transferase, long chain base subunit 2
  CD109                                                                                                                   8120719                        -1.88                               -1.49                              -4.35                                  226545_at                                                   CD109 molecule
  TMX4                                                                                                                    8064939                        -1.85                               -1.61                              -2.67                                  201580_s\_at                                                thioredoxin-related transmembrane protein 4
  CCBE1                                                                                                                   8023575                        -1.85                               -1.59                              -1.83                                  243805_at                                                   collagen and calcium binding EGF domains 1
  FAM46A                                                                                                                  8127778                        -1.84                               -1.68                              -1.90                                  224973_at                                                   family with sequence similarity 46, member A
  EPHA5                                                                                                                   8100578                        -1.83                               -1.86                              -2.42                                  237939_at                                                   EPH receptor A5
  SPON1                                                                                                                   7938608                        -1.82                               -1.84                              -2.13                                  213994_s\_at                                                spondin 1, extracellular matrix protein
  ABCG2                                                                                                                   8101675                        -1.81                               -1.94                              -3.01                                  209735_at                                                   ATP-binding cassette, sub-family G (WHITE), member 2
  RSPO3                                                                                                                   8121916                        -1.75                               -1.92                              -2.21                                  228186_s\_at                                                R-spondin 3 homolog (Xenopus laevis)
  CLIC2                                                                                                                   8176234                        -1.74                               -1.54                              -2.68                                  213415_at                                                   chloride intracellular channel 2
  SLC18A2                                                                                                                 7930837                        -1.68                               -1.78                              -2.58                                  205857_at                                                   solute carrier family 18 (vesicular monoamine), member 2
  PRICKLE2                                                                                                                8088550                        -1.67                               -1.48                              -2.83                                  225968_at                                                   prickle homolog 2 (Drosophila)
  KLHL13                                                                                                                  8174654                        -1.61                               -1.51                              -2.31                                  227875_at                                                   kelch-like 13 (Drosophila)
  PLA2R1                                                                                                                  8056151                        -1.59                               -1.51                              -1.51                                  207415_at                                                   phospholipase A2 receptor 1, 180kDa
  PLD1                                                                                                                    8092134                        -1.57                               -1.47                              -1.59                                  226636_at                                                   phospholipase D1, phosphatidylcholine-specific
  WT1                                                                                                                     7947363                        -1.53                               -1.82                              -2.49                                  216953_s\_at                                                Wilms tumor 1
  C17orf58                                                                                                                8017831                        -1.48                               -1.45                              -1.87                                  226901_at                                                   chromosome 17 open reading frame 58
  TWISTNB                                                                                                                 8138454                        -1.46                               -1.65                              -2.81                                  226784_at                                                   TWIST neighbor
  LONRF2                                                                                                                  8054281                        -1.46                               -2.44                              -3.55                                  225996_at                                                   LON peptidase N-terminal domain and ring finger 2
  SERPINE1                                                                                                                8135069                        1.45                                1.65                               3.39                                   1568765_at                                                  serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
  IER3                                                                                                                    8124848                        1.48                                                                   5.13                                   201631_s\_at                                                immediate early response 3
  EIF4A1                                                                                                                  8004506                        2.01                                1.60                               1.89                                   214805_at                                                   Eukaryotic translation initiation factor 4A1
  TBRG4                                                                                                                   8139482                        2.12                                1.73                               2.93                                   220789_s\_at                                                transforming growth factor beta regulator 4
  IGFBP5                                                                                                                  8058857                        3.28                                3.24                               2.45                                   203425_s\_at                                                insulin-like growth factor binding protein 5
  IER3                                                                                                                    8178435                                                            1.47                               5.13                                   201631_s\_at                                                immediate early response 3
  **eSF E2+P4 treated in common with WHOLE Tissue MSE in Disease vs Control**                                                                                                                                                                                                                                                      
                                                                                                                          In Vitro array.Probe.Set. ID   FC (\[Endo IV-EP\] vs \[NUP-EP\])   FC (\[Endo I-EP\] vs \[NUP-EP\])   FC (\[MSE.Endo\] vs \[MSE.Control\])   Tissue array. Probe.Set.ID                                  Gene Title
  LPL                                                                                                                     8144917                        -4.54                               -5.48                              -1.62                                  203548_s\_at                                                lipoprotein lipase
  LGR4                                                                                                                    7947199                        -3.35                               -3.41                              -3.15                                  218326_s\_at                                                leucine-rich repeat-containing G protein-coupled receptor 4
  GREB1                                                                                                                   8040292                        -3.19                               -4.97                              -2.10                                  205862_at                                                   growth regulation by estrogen in breast cancer 1
  F3                                                                                                                      7917875                        -2.92                               -2.11                              -2.50                                  204363_at                                                   coagulation factor III (thromboplastin, tissue factor)
  CAB39L                                                                                                                  7971590                        -2.64                               -2.33                              -2.62                                  225915_at                                                   calcium binding protein 39-like
  SPARCL1                                                                                                                 8101659                        -2.28                               -2.92                              -1.91                                  200795_at                                                   SPARC-like 1 (hevin)
  GPR155                                                                                                                  8056837                        -2.24                               -2.50                              -1.63                                  239533_at                                                   G protein-coupled receptor 155
  FAM134B                                                                                                                 8111136                        -2.23                               -2.76                              -2.14                                  218532_s\_at                                                family with sequence similarity 134, member B
  RORB                                                                                                                    8155864                        -2.19                               -2.73                              -2.93                                  242385_at                                                   RAR-related orphan receptor B
  THSD7A                                                                                                                  8138231                        -2.10                               -4.77                              -2.28                                  214920_at                                                   thrombospondin, type I, domain containing 7A
  ADAMTS9                                                                                                                 8088560                        -2.09                               -2.27                              -2.74                                  226814_at                                                   ADAM metallopeptidase with thrombospondin type 1 motif, 9
  PRLR                                                                                                                    8111490                        -2.03                               -2.67                              -2.91                                  206346_at                                                   prolactin receptor
  LPAR1                                                                                                                   8163257                        -2.02                               -2.14                              -1.76                                  204037_at                                                   lysophosphatidic acid receptor 1
  ATP13A3                                                                                                                 8092849                        -2.02                               -2.22                              -1.58                                  212297_at                                                   ATPase type 13A3
  ADAMTS5                                                                                                                 8069689                        -1.99                               -2.11                              -3.14                                  229357_at                                                   ADAM metallopeptidase with thrombospondin type 1 motif, 5
  SAT1                                                                                                                    8166469                        -1.95                               -2.20                              -2.66                                  213988_s\_at                                                spermidine/spermine N1-acetyltransferase 1
  APOO                                                                                                                    8171823                        -1.94                               -1.78                              -2.29                                  221620_s\_at                                                apolipoprotein O
  CNKSR2                                                                                                                  8166355                        -1.91                               -1.97                              -1.79                                  229116_at                                                   connector enhancer of kinase suppressor of Ras 2
  ABHD5                                                                                                                   8079153                        -1.74                               -1.91                              -2.59                                  213935_at                                                   abhydrolase domain containing 5
  CTSS                                                                                                                    7919800                        -1.67                               -1.56                              -1.79                                  202902_s\_at                                                cathepsin S
  ANGPT2                                                                                                                  8149071                        -1.66                               -1.65                              -1.86                                  205572_at                                                   angiopoietin 2
  CADM1                                                                                                                   7951807                        -1.64                               -1.87                              -3.47                                  209032_s\_at                                                cell adhesion molecule 1
  ZCCHC6                                                                                                                  8162147                        -1.63                               -1.87                              -2.25                                  220933_s\_at                                                zinc finger, CCHC domain containing 6
  SESTD1                                                                                                                  8057394                        -1.63                               -1.95                              -2.31                                  226763_at                                                   SEC14 and spectrin domains 1
  KAL1                                                                                                                    8171248                        -1.62                               -1.91                              -1.97                                  205206_at                                                   Kallmann syndrome 1 sequence
  ETS2                                                                                                                    8068593                        -1.60                               -1.46                              -1.56                                  201328_at                                                   v-ets erythroblastosis virus E26 oncogene homolog 2 (avian)
  TSPAN12                                                                                                                 8142524                        -1.54                               -1.52                              -2.14                                  219274_at                                                   tetraspanin 12
  MDM1                                                                                                                    7964810                        -1.51                               -1.58                              -3.31                                  213761_at                                                   Mdm1 nuclear protein homolog (mouse)
  TSPAN13                                                                                                                 8131600                        -1.51                               -1.52                              -1.69                                  217979_at                                                   tetraspanin 13
  TMEM133                                                                                                                 7943369                        -1.48                               -1.52                              -1.77                                  223595_at                                                   transmembrane protein 133
  ARRDC4                                                                                                                  7986350                        -1.47                               -1.90                              -2.41                                  225283_at                                                   arrestin domain containing 4
  FERMT2                                                                                                                  7979204                        -1.45                               -1.89                              -2.29                                  209209_s\_at                                                fermitin family member 2
  TBRG4                                                                                                                   8139482                        1.99                                1.57                               2.35                                   220789_s\_at                                                transforming growth factor beta regulator 4
  **eSF signature in Disease vs Control in E2, or E2+P4 treated eSF common with FACS sorted eSF in Disease vs Control**                                                                                                                                                                                                            
  **Compared to E2 treatment**                                                                                                                                                                                                                                                                                                     
                                                                                                                          In Vitro array.Probe.Set. ID   FC (\[Endo IV-E\] vs \[NUP-E\])     FC (\[Endo I-E\] vs \[NUP-E\])     FC eSF FACS Endo vs eSF FACS control   Gene Title                                                   
  TNXB\|TNXA                                                                                                              8179935                        -2.53                               -1.83                              -2.32                                  tenascin XB \| tenascin XA pseudogene                       
  LCP1                                                                                                                    7971461                        -2.12                               -2.66                              -2.12                                  lymphocyte cytosolic protein 1 (L-plastin)                  
  FAM134B                                                                                                                 8111136                        -2.09                               -1.82                              -1.64                                  family with sequence similarity 134, member B               
  IL17RB                                                                                                                  8080562                        -1.93                               -2.36                              -2.06                                  interleukin 17 receptor B                                   
  TGFBR3                                                                                                                  7917649                        -1.80                               -1.57                              -1.97                                  transforming growth factor, beta receptor III               
  ABI3BP                                                                                                                  8089145                        -1.76                               -2.10                              -1.91                                  ABI family, member 3 (NESH) binding protein                 
  KLHL13                                                                                                                  8174654                        -1.61                               -1.51                              -1.55                                  kelch-like 13 (Drosophila)                                  
  SNORD46                                                                                                                 7901048                        1.90                                1.74                               1.76                                   small nucleolar RNA, C/D box 46                             
  SERTAD4                                                                                                                 7909503                        2.28                                2.04                               1.54                                   SERTA domain containing 4                                   
  RGS4                                                                                                                    7906919                        2.36                                2.89                               1.90                                   regulator of G-protein signaling 4                          
  SULF1                                                                                                                   8146863                        3.79                                2.31                               1.61                                   sulfatase 1                                                 
  **Compared to E2+P4 Treatment**                                                                                                                                                                                                                                                                                                  
                                                                                                                          In Vitro array.Probe.Set. ID   FC (\[Endo IV-EP\] vs \[NUP-EP\])   FC (\[Endo I-EP\] vs \[NUP-EP\])   FC eSF FACS Endo vs eSF FACS control   Gene Title                                                   
  ABI3BP                                                                                                                  8089145                        -2.36                               -6.50                              -1.91                                  ABI family, member 3 (NESH) binding protein                 
  ADAMTS5                                                                                                                 8069689                        -1.99                               -2.11                              -1.87                                  ADAM metallopeptidase with thrombospondin type 1 motif, 5   
  CRISPLD2                                                                                                                7997642                        -1.58                               -1.88                              -1.55                                  cysteine-rich secretory protein LCCL domain containing 2    
  FAM134B                                                                                                                 8111136                        -2.23                               -2.76                              -1.64                                  family with sequence similarity 134, member B               
  KIAA0040                                                                                                                7922474                        -2.46                               -2.33                              -1.50                                                                                              
  LCP1                                                                                                                    7971461                        -2.12                               -2.90                              -2.12                                  lymphocyte cytosolic protein 1 (L-plastin)                  
  MAOB                                                                                                                    8172204                        -2.24                               -3.23                              -1.54                                  monoamine oxidase B                                         
  PARM1                                                                                                                   8095751                        -1.90                               -1.56                              -2.30                                  prostate androgen-regulated mucin-like protein 1            
  SERTAD4                                                                                                                 7909503                        1.67                                1.71                               1.54                                   SERTA domain containing 4                                   
  SNORD46                                                                                                                 7901048                        2.16                                1.60                               1.76                                   small nucleolar RNA, C/D box 46                             
  SULF1                                                                                                                   8146863                        2.12                                1.67                               1.61                                   sulfatase 1                                                 
  TMEM37                                                                                                                  8044813                        -1.61                               -2.23                              -1.54                                  transmembrane protein 37                                    
  ----------------------------------------------------------------------------------------------------------------------- ------------------------------ ----------------------------------- ---------------------------------- -------------------------------------- ----------------------------------------------------------- -----------------------------------------------------------------------------------------------

Comparing MSE tissue and E~2~+P~4~-treated eSF~stage-I~ and eSF~stage-IV~ vs normal, pathway analysis revealed common signaling pathways involving PI3K-Akt, Rap1 and Ras, and cancer (**[S15 Table](#pgen.1008601.s018){ref-type="supplementary-material"}**).

Comparing transcriptomes of cultured eSF~endo~ and eSF~normal~ and freshly isolated (uncultured) FACS-sorted eSF~endo~ and eSF~normal~ from human eutopic endometrium \[[@pgen.1008601.ref020]\] revealed many shared genes (**[Table 6](#pgen.1008601.t006){ref-type="table"}**; **[S16 Table](#pgen.1008601.s019){ref-type="supplementary-material"}**). Note that FACS-sorted eSF~normal~ and eSF~endo~ included samples from various cycle phases, different disease stages \[[@pgen.1008601.ref020]\], and a more limited sample number compared to the bulk tissue study. Thus, the number of overlapping loci in cultured and freshly isolated eSF is expectedly smaller than those shared with whole tissue.

Together, the extent of overlap with whole tissue samples and FACS isolated eSF indicates the *in vitro* hormonal treatment of eSF, the predominant cell type in endometrium, is a good model and reflects a persistent eSF signature in the whole tissue.

Histone H3K27me3 and H3K27ac modifications in response to E~2~ {#sec017}
--------------------------------------------------------------

Since E~2~ induced the largest changes in the DNA methylome of eSF, we sought to assess its effect on the histone marks to better understand how E~2~ affected the regulatory function of the epigenetic machinery. We assessed silencing and activating histone modifications, H3K27me3, and H3K27ac, using chromatin immunoprecipitation followed by deep sequencing (ChIP-Seq). Modifications of H3K27me3, and H3K27ac have been found in loci involved in eSF decidualization \[[@pgen.1008601.ref010],[@pgen.1008601.ref011],[@pgen.1008601.ref027]\]. In response to E~2~ we observed more differential peaks in H3K27ac than H3K27me3 in line with our observation of more loss of DNA methylation corresponding to a more open chromatin state induced by E~2~ **([S17 Table](#pgen.1008601.s020){ref-type="supplementary-material"}** for peaks associated with each histone mark**).** GO gene functional analysis for each histone modification renriched pathways related to regulation of signaling, cell morphogenesis and differentiation, G-protein coupled receptor signaling, regulation of mitotic cell cycle and intracellular protein transport among others, many of which are shared with DNA methylation data **([S17 Table](#pgen.1008601.s020){ref-type="supplementary-material"}** for pathways for each histone mark**).**

Association of PGR target loci identified in E~2~+cAMP+MPA decidualization and E~2~+P~4~ induced DNA methylation {#sec018}
----------------------------------------------------------------------------------------------------------------

Increased binding of PGR to open chromatin was shown previously in decidualizing cells by ChIP-Seq experiments \[[@pgen.1008601.ref010],[@pgen.1008601.ref027]\] and that the presence of PGR binding site and its putative co-regulator FOSL2 in a genomic location is associated with open chromatin during decidualization \[[@pgen.1008601.ref010],[@pgen.1008601.ref011]\]. Moreover, direct PGR targets in eSF treated for 72hrs with E~2~+MPA+cAMP were identified by Mazur *et*. *al*., using ChIP-Seq and RNA-Seq \[[@pgen.1008601.ref010]\]. We assessed the overlap of the E~2~+P~4~ induced differentially methylated CpG sites associated with genes in normal, stage I and stage IV disease to genes with PGR binding sites present in the Mazur *et*. *al*. study within the extended promoter region (as defined to be -7500bp and +2500bp from TSS) and intervals within ±10KB, as well as ±25KB from transcriptional start/stop site in normal eSF. We found a small subset of genes overlapping in normal eSF (**[Table 7](#pgen.1008601.t007){ref-type="table"}**); however, these common genes were enriched for biofunctions that are involved in cell morphogenesis, differentiation and cell projections, endosome organization and cytoskeletal organization (**[Table 7](#pgen.1008601.t007){ref-type="table"}**). These are important during decidualization as eSF decidualization is characterized by morphological changes, expansion/restructuring of extracellular matrix, surface projections and expansion of endoplasmic reticulum. Interestingly, a larger number of genes in stage I and IV overlapped with PGR binding sites than normal eSF (**[Table 7](#pgen.1008601.t007){ref-type="table"}**). Stage IV and normal shared more common genes with PGR binding sites than they did with stage I (**[Table 7](#pgen.1008601.t007){ref-type="table"}**). Biofunction analysis showed more biofunctions involved in stage I than normal, such as tissue morphogenesis, response to TGF-beta signaling, response to growth factor and extracellular matrix among others (**[Table 7](#pgen.1008601.t007){ref-type="table"}**). In stage IV, the biofunctions involved negative regulation of Wnt signaling, and intracellular signal transduction (**[Table 7](#pgen.1008601.t007){ref-type="table"}**) known to be affected in endometriosis. These data further support the notion of aberrant P~4~ response, rather than P~4~-resistance in endometriosis.

10.1371/journal.pgen.1008601.t007

###### Differentially methylated (DM) genes with PGR binding sites affected by E~2~+P~4~ treatment in normal eSF (NUP), stage I eSF (Endo I) and stage IV eSF (Endo IV) and the associated pathways by GO analysis in DAVID.

![](pgen.1008601.t007){#pgen.1008601.t007g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **DM genes with PGR binding sites in E2+P4 treated NUP**                                                                                                                                                                                                                                                                                                                                                                   **DM genes with PGR binding sites in E2+P4 treated Endo I**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             **DM genes with PGR binding sites in E2+P4 treated Endo IV**

  ***AFF1*, *ASH1L*, *C3orf21*, *CAP2*, *ELK3*, *CLSTN2*, *LOC442459*, *MYH13*, *MYLK4*, *NSMCE2*, *NUBPL*, *PHACTR1*, *RBM46*, *SAV1*, *SOX5*, *SPAG16*, *TBC1D1*, *TMEM232*, *TOP2B*, *WDR27*, *WWC3*, *NLK*[\*\*\*](#t007fn003){ref-type="table-fn"}, *TTL***[\*\*\*](#t007fn003){ref-type="table-fn"}\                                                                                                                   ACTG2, ANKRD11, AP4E1, ARHGAP12, ARHGAP15, ATF6, BCAS1, C13orf26, C15orf61, CDH6, CLASP2, COL1A2, CPEB4,CROCC, CSTF3, DIRC3, DOPEY1, DSEL, EBF1, EYS, FARP1, FBN1, FBN3, FBXL2, FIGN, FLJ43860, FRAS1, FSIP1, GLI3, GLIS1, GNG7, GPR143, GPR176, GRID2, HERC2, HHLA2, HTRA3, ICA1L, INTS3, IQGAP2, IQGAP3, ITGA8, ITGB5, KCTD9, KDM4B, KIF26B, LOC285692, LRBA, LRRC8C, LTBP2, MAGI2, MED13L, METAP2, MYH8, NFIB, NHS, NOTCH4, NTM, PACSIN3, PCNX, PCNXL2, PDE3B, PLCG2, PPM1H, PRIM2, PTBP2, PTPN4, PTPRG, RGS7, RHOQ, ROBO1, RPS6KA2, RTKN2, SHROOM3, SLC44A1, SLIT3, SNTB1, SYNPR, TBX4, TGFBR3, THSD4, THSD7B, TNC, TRIO, UTRN,VWA3B, ZDHHC6, RBM20[\*](#t007fn001){ref-type="table-fn"}, SRBD1[\*](#t007fn001){ref-type="table-fn"}, NLK[\*\*\*](#t007fn003){ref-type="table-fn"}, TTL[\*\*\*](#t007fn003){ref-type="table-fn"}, CNTNAP5[\*\*](#t007fn002){ref-type="table-fn"}, ITGBL1[\*\*](#t007fn002){ref-type="table-fn"}, ZNF275[\*\*](#t007fn002){ref-type="table-fn"}\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ***AFF1*, *ASH1L*, *C3orf21*, *CAP2*, *ELK3*, *CLSTN2*, *LOC442459*, *MYH13*, *MYLK4*, *NSMCE2*, *NUBPL*, *PHACTR1*, *RBM46*, *SAV1*, *SOX5*, *SPAG16*, *TBC1D1*, *TMEM232*, *TOP2B*, *WDR27*, *WWC3*, *NLK*[\*\*\*](#t007fn003){ref-type="table-fn"}, *TTL***[\*\*\*](#t007fn003){ref-type="table-fn"}\
  ATP8A2, C1QTNF9B, C8orf44, CACNA2D3, CDC73, CSRNP3, FMN1, GPM6B, HSD17B2, INPP5A, JPH1, KIAA1033, MCF2, MGAT4C, NEK10, ODZ2, OXR1, PIK3C3, PLXNC1, PTPRQ, RAB3C, SEMA5A, SGIP1, SNX25, SRGAP1, TBC1D4, TNFRSF9, VENTXP1, VTA1, WBP4, YEATS4, RBM20[\*](#t007fn001){ref-type="table-fn"}, SRBD1[\*](#t007fn001){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ACER3, ARL15, ATP8B4, C10orf11, C16orf62, C17orf104, C17orf67, COL14A1, CREB5, DCBLD1, DENND2A, DLC1, DOCK4, EFR3A, FAM155A, FAM188A, FAM73A, FKBP5, FYCO1, GAL3ST2, GALNTL6, GULP1, HPS3, IGF1R, IL31RA, KIAA0564, KLHL29, LRRC16A, MOXD1, MYO1E, NMBR, NXN, PDE4DIP, PPFIA2, PSMD14, RECK, RGL1, SCHIP1, SIK3, SLC2A13, SNX29, SPSB1, ST7, TEAD1, TNFRSF1B, UST, WWTR1, YWHAQ, ITGBL1[\*\*](#t007fn002){ref-type="table-fn"}, CNTNAP5[\*\*](#t007fn001){ref-type="table-fn"}, ZNF275[\*\*](#t007fn002){ref-type="table-fn"}

  **Pathways of DM genes with PGR binding sites in E2+P4 treated NUP (P\<0.05)**                                                                                                                                                                                                                                                                                                                                             **Pathways of DM genes with PGR binding sites in E2+P4 treated Endo I (P\<0.05)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       **Pathways of DM genes with PGR binding sites in E2+P4 treated Endo IV (P\<0.05)**

  Cellular component morphogenesis; cell morphogenesis; cell part morphogenesis;single-organism organelle organization; cytoskeleton organization; endosome organization; neuron development; cell morphogenesis involved in differentiation; cell projection morphogenesis; negative regulation of developmental growth; neuron projection development; regulation of axon extension; regulation of extent of cell growth   Tissue morphogenesis; cellular response to transforming growth factor beta stimulus; organ morphogenesis; morphogenesis of an epithelium; metanephros development; extracellular matrix organization; animal organ development; system development; cell morphogenesis involved in differentiation; response to growth factor; epithelium development; cell development; urogenital system development; neuron projection development; cell morphogenesis; neuron development; anatomical structure formation involved in morphogenesis; cellular component morphogenesis; cellular component morphogenesis; kidney development; cell surface receptor signaling pathway; renal system development; cellular response to organic substance; regulation of cellular response to transforming growth factor beta stimulus; negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway; gland development; odontogenesis; embryonic morphogenesis; regulation of transmembrane receptor protein serine/threonine kinase signaling pathway; regulation of cell projection organization; neuron projection guidance; signal transduction; tube morphogenesis; mammary gland development; regulation of signal transduction; telencephalon cell migration; circulatory system development; negative regulation of cellular component movement; forebrain cell migration; negative regulation of cellular response to transforming growth factor beta stimulus; forebrain generation of neurons; regulation of neurogenesis; brain development; tangential migration from the subventricular zone to the olfactory bulb; regulation of cell development   Negative regulation of Wnt signaling pathway; intracellular signal transduction; single-organism organelle organization
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\* Common in NUP and Endo I

\*\* Common in Endo I and Endo IV

\*\*\* Common in NUP, Endo I and Endo IV; ***Bold Italics***, common in NUP and Endo IV

Discussion {#sec019}
==========

Unique steroid hormone effects on normal endometrial stromal fibroblasts {#sec020}
------------------------------------------------------------------------

The eSF is the most abundant steroid hormone-responsive cell in endometrium and is a master regulator of tissue function and pregnancy success, and thus how the steroid hormones E~2~ and P~4~ regulate the epigenome and transcriptional machinery in this cell type in a timeline similar to *in vivo* exposure is of high priority in understanding normal and abnormal eSF function in women. Effects of E~2~ and P~4~ alone on the hormone-epigenome interplay has largely been studied in breast cancer cell lines, providing key insights into hormone receptor topology, epigenetic genomic alterations, transcriptional regulation, and chromatin dynamics \[[@pgen.1008601.ref028],[@pgen.1008601.ref029]\]. As these complex interactions are cell- and tissue-specific, extrapolating their properties to normal endometrium is limited, although a few studies have investigated the effects of E~2~ plus progestins, such as medroxyprogesterone acetate, in the presence of cAMP on eSF for 72 hrs \[[@pgen.1008601.ref010]\] or longer with or without glucose in the culture medium on chromatin accessibility or histone marks \[[@pgen.1008601.ref009],[@pgen.1008601.ref011]\]. These studies show altered chromatin accessibility in eSF decidualized with E~2~+MPA+cAMP \[[@pgen.1008601.ref011]\] and provide significant insights into PGR binding across the genome and association with open chromatin \[[@pgen.1008601.ref010]\].

The current study investigated the effects of estradiol, progesterone (individually) and their combination (without cAMP or other progestins) on the DNA methylome and transcriptome and their interplay in normal eSF at 14 days, mimicking *in vivo* exposure times. Moreover, we compared eSF from the inflammatory disorder, endometriosis, in the setting of lesser and more advanced stage disease to the normal eSF. The data herein revealed, for the first time, that E~2~ and P~4~ individually and together promote unique patterns and profiles in the normal DNA methylome of this cell type. E~2~ alone elicited broad changes, blunted by P~4~, and mostly result in open chromatin by inducing more loss of methylation and increased H3K27ac histone mark. Progesterone alone had a limited effect on the DNA methylome, and unlike E~2,~ elicited loss and gain of methylation equally. E~2~+P~4~ affected the epigenome less robustly than E~2~ alone, but showed more loss than gain of methylation. In support of our observation Vrljicak *et*. *al*. using transposase accessible chromatin followed by sequencing (ATAC-Seq) found altered chromatin accessibility with more open than closed chromatin loci after 4days treatment with MPA and cAMP \[[@pgen.1008601.ref011]\]. These data suggest that E~2~ and P~4~ interact differently with the epigenome when combined than when individually administered suggestive of different mechanisms involved in the response of eSF to E~2~ and to P~4~ individually and in combination. Hormone-specific patterns and profiles were abnormal in both disease stages with more severe abnormalities associated with stage IV disease. The range of differences in individual loci with differential methylation and the number of enriched clusters and gene functions induced by each hormonal treatment in disease versus normal suggest inherent differences in disease and disease stages. However, in disease, as in normal, E~2~ induced more extensive alteration than E~2~+P~4~ followed by P~4~. Despite these differences, hormone-induced changes overall mainly involved CpG sites at the 3'end, intergenic regions, and enhancers, limited involvement of 5'end and 1^st^ exons and rarely involved CpG sites in close proximity to transcription start sites (TSS200) or CpG islands. Notably, E~2~ treatment of MCF-7 breast cancer cells also demonstrated minimal binding of ER to proximal promoter regions (up to 5kb) \[[@pgen.1008601.ref030]\], despite their containing the majority of known EREs.

Whereas CpG sites in CpG islands (CGI) were minimally affected, CGI shores and shelves were more involved, regardless of methylation loss or gain or the type of hormone treatment, indicating a specific genome landscape interaction of hormones in this endometrial cell type. Whether the lack of involvement of CGIs reflects regulation of genes whose functions are not regulated by direct or indirect hormone-targeted mechanisms, or whether hormone response elements are not affected in CGIs is yet to be determined. In breast cancer cell lines gene expression \[[@pgen.1008601.ref031]\] and DNA methylation profiles \[[@pgen.1008601.ref032]\] as well as DNA methylation at several candidate genes at their CGIs \[[@pgen.1008601.ref033]\] depend on their ER and PR status. This observation further highlights findings herein that the majority of differentially methylated loci in eSF~normal~ are located in the intergenic regions, 3'UTRs and enhancers, and do not involve regions in close proximity to TSS, 5'UTR and 1^st^ exons, where most CpG islands are located.

Epigenetic signatures in endometriosis: Hormone response, disease subtypes, pre-existing abnormalities {#sec021}
------------------------------------------------------------------------------------------------------

Women with endometriosis have high prevalence of infertility with otherwise unknown etiologies and lower implantation, clinical pregnancy and live birth rates compared to those without disease \[[@pgen.1008601.ref034]\]. Studies in humans \[[@pgen.1008601.ref035]\] and animal models \[[@pgen.1008601.ref036]\] suggest compromised implantation attributed, in part, to an abnormal response to P~4~ and the inflammatory milieu of the endometrium. The current study confirmed abnormal P~4~-regulated decidualization marker expression in eSF~endo~, largely attributed to "P~4~-resistance", although P~4~ did have effects across the eSF~endo~ genome and PGR targets. However, eSF~endo~ additionally had different responses to E~2~ compared to eSF~normal~, which likely also contributes to abnormal endometrial function in women with disease (as described below). Of note, aberrant lack of ERα down-regulation at the time of implantation in endometrium of endometriosis women is considered key in implantation failure in women with disease \[[@pgen.1008601.ref037]\]. However, endometrial-based infertility and effects on pregnancy outcomes are controversial, as large studies on IVF/ICSI outcomes in women with endometriosis and ovarian endometriomas revealed no differences in pregnancy rates \[[@pgen.1008601.ref038],[@pgen.1008601.ref039]\] or a significant difference in endometrial receptivity array test in women with endometriosis versus controls \[[@pgen.1008601.ref040]\]. How the aberrancies observed herein in P~4~-, or E~2~-induced epigenetic signatures are linked with implantation outcomes in women with endometriosis warrants further investigation.

Whether stage I and stage IV endometriosis are distinct disease sub-types has been the subject of debate. That eSF~stage-I~ differ greatly from eSF~stage-IV~ in hormone response supports distinct disease subtypes. Also, disparities in the DNA methylomes of eSF~stage-I~ and eSF~stage-IV~ *before* hormonal treatments further support distinct disease subtypes. The latter observation underscores pre-existing abnormalities in the eSF epigenome in the setting of endometriosis, and the data showed eSF~stage-IV~ with more extensive pre-existing differences affecting its responses, compared to eSF~stage-I~.

This is consistent with previous findings that the endometrial bulk tissue transcriptome differs between the two stages \[[@pgen.1008601.ref018],[@pgen.1008601.ref026]\] and several endometriosis genome-wide analysis studies suggestive of a stronger genetically driven component for stage IV than stage I disease \[[@pgen.1008601.ref041]\]. Of note, clinically, women with stage IV versus stage I endometriosis have significantly lower implantation rates (13.7% vs. 28.3%, respectively), pregnancy rates (22.6% vs. 40.0%, respectively) \[[@pgen.1008601.ref042]\], and lower IVF pregnancy rates (13.84% vs. 21.12% respectively) \[[@pgen.1008601.ref043]\]- believed due to endometrial abnormalities that reflect distinct subtypes of disease. Mapping hormone-genome interactions of these subtypes holds promise for innovative, targeted therapies to modify pre-existing and stage-specific abnormalities in endometrium of women with endometriosis and optimize endometrial receptivity for implantation and pregnancy success of women with endometriosis.

Dyson *et*. *al*. \[[@pgen.1008601.ref044]\] have observed aberrant DNA methylation in the stromal fibroblast isolated from the endometriotic ectopic lesion. It remains to be determined whether and to what extent the ectopic lesion aberrances stem from the eutopic endometrial stromal fibroblasts.

Recently, Maekawa *et*. *al*. assessed the genome-wide methylome changes during decidualization and in contrast to our data reported no changes in the DNA methylome \[[@pgen.1008601.ref045]\]. DNA methylation distribution follows a bimodal distribution with the majority of CpG sites either hypomethylated or hypermethylated \[[@pgen.1008601.ref046]\], as also reported in their study as well as in the current study and as we have previously observed in normal and endometriosis endometrium \[[@pgen.1008601.ref014],[@pgen.1008601.ref015]\] Furthermore, we have also observed that the majority of CpG sites remain unchanged in decidualized versus non-decidualized eSF. The differences in our observation could be due to different analyses methods, where Maekawa *et*. *al* limited the definition of differential methylation to \>Δβ of 0.3, which would not detect smaller changes. In our analyses we considered smaller changes in the DNA methylome but with the stringency that they were observed in at least 75% of each sample group. Another reason could be due to differences in the samples, where we used normal controls while patients with myoma or cervical cancer were used in their study, or it is likely that E~2~+MPA used in that study affects the epigenome differently than E~2~+P~4~ in our study.

Progesterone "resistance" {#sec022}
-------------------------

Pursuing bulk tissue transcriptomic analysis, we first described "P~4~ resistance" in endometrium from women with endometriosis \[[@pgen.1008601.ref008],[@pgen.1008601.ref035]\] a phenomenon also observed by others \[[@pgen.1008601.ref047]--[@pgen.1008601.ref049]\]. In samples obtained in the implantation window and timed to the LH surge, there was evidence for impaired expression of key epithelial and stromal fibroblast markers of embryo receptivity and decidualization, respectively \[[@pgen.1008601.ref035]\]. Analysis of endometrium across the menstrual cycle from women with severe disease strikingly revealed persistent E~2~-regulated genes in the early secretory phase, consistent with impaired P~4~ action \[[@pgen.1008601.ref008]\]. Moreover, these data were substantiated in a larger cohort \[[@pgen.1008601.ref026]\], that also revealed a marked pro-inflammatory phenotype within the endometrium of women with disease. Inflammation can cause epigenetic changes in endometrium as demonstrated in an animal model of the disease \[[@pgen.1008601.ref050]\]. We and others found P~4~-resistance in eSF \[[@pgen.1008601.ref019],[@pgen.1008601.ref051]\]. Notably, inflammatory cytokines (e.g., IL-1β and TNFα) epigenetically silence the eSF PR, promoting P~4~-resistance with diminished expression of decidualization markers IGFBP1 and prolactin \[[@pgen.1008601.ref050],[@pgen.1008601.ref052]\] and enhanced secretion of matrix metalloproteinases, which are normally suppressed in eSF by P~4~ \[[@pgen.1008601.ref053]\]. Epigenetic mechanisms underlying P~4~-resistance in endometriosis have mostly focused on the disease itself (as opposed to the eutopic endometrium studied herein) which exhibits P~4~ and progestin resistance for pain relief initially or acquired over time \[[@pgen.1008601.ref054]\].

We suggest that the nomenclature of "P~4~ resistance" be re-evaluated, since the data herein show eSF~endo~ respond to P~4~ with regard to epigenetic marks, PGR target sites, and gene expression, albeit differently from eSF~normal~, although they do not fully decidualize. Notably, endometrium of women with disease does not retain a proliferative phenotype throughout the cycle \[[@pgen.1008601.ref006],[@pgen.1008601.ref008]\], although there is compromised implantation in women with disease \[[@pgen.1008601.ref035],[@pgen.1008601.ref052]\]. Importantly, "P~4~ -resistance" was observed in endometrium of non-pregnant women who previously had severe pre-eclampsia, and this was also found in the decidua at delivery of women with this disorder \[[@pgen.1008601.ref055]\], underscoring the need to understand this process for normal pregnancy. Thus, P~4~ signaling in the endometrium and aberrancies in decidualization therein *in vivo* are likely influenced by other cell types in the tissue, including the inflammatory status of the individual and warrant further investigation.

Abnormal response to E~2~ {#sec023}
-------------------------

Herein, for the first time the observations have been made that in addition to aberrant eSF~endo~ P~4~ response, eSF from women with endometriosis show vastly aberrant responses to E~2.~ Specifically, E~2~-induced eSF DNA methylation changes blunted in stage IV disease and were more extensive in stage I. Loci with strong associations of DNA methylation and gene expression had distinct enrichment in gene functions in stage I and stage IV, including ion channels, ATP and nucleotide binding in stage I and plasma membrane and signaling in stage IV, suggesting functional impairment of eSF from women with versus without endometriosis. Moreover, they underscore that not only is the eSF response to P~4~ abnormal in women with disease, but also *their response to E*~*2*~ *is abnormal*. The latter has received little attention in the endometriosis literature, which is surprising, as the disorder is estrogen-dependent \[[@pgen.1008601.ref012],[@pgen.1008601.ref021]\]. As eSF normally require E~2~ priming prior to the full decidualization P~4~ response, it is not unanticipated that with abnormal E~2~ signaling in eSF, P~4~ signaling would also be disrupted. Aromatase, essential for E~2~ production, as well as E~2~ levels are highly expressed in endometriotic tissue \[[@pgen.1008601.ref056]--[@pgen.1008601.ref059]\] with an increased COX2 expression in turn resulting in increased E~2~ production in a positive feedback loop in ectopic and eutopic tissue of endometriosis patients \[[@pgen.1008601.ref057]\]. Whether the aberrant response to E~2~ observed herein could be affected by these aberrancies in E~2~ production in endometriosis remains to be determined.

Potential mechanisms of E~2~-epigenome interactions {#sec024}
---------------------------------------------------

The binding of some hormone NRs commonly occurs at accessible regions of the chromatin before hormone induction \[[@pgen.1008601.ref060]\] or their recruitment occurs almost equally at the nucleosome-occupied and nucleosome-free states before hormone induction \[[@pgen.1008601.ref061]\]. E~2~ (biological active estrogen) enters cells, binds to subtypes of ERα and β that have high affinity for E~2~ and are encoded by different genes \[[@pgen.1008601.ref062]\]. While both ER subtypes are expressed in human endometrium, ERα is the primary mediator of E~2~ action in this tissue \[[@pgen.1008601.ref063]\]. ERα recruitment is complex involving multiple mechanisms depending on cell type and culture conditions \[[@pgen.1008601.ref064]\]. ERα can bind to compact chromatin while there are abundant accessible regions before E~2~ induction that will further recruit ERα \[[@pgen.1008601.ref065]\]. The DNA methylation and histone modification findings herein suggest that E~2~ can increase open chromatin. Chromatin accessibility can be induced by ERα binding, as these accessible clusters are found near estrogen-target genes \[[@pgen.1008601.ref066]\]. While increased open chromatin was found in eSF~normal~ in response to E~2~, the opposite was found in eSF~endo~. This could be due to pre-existing abnormalities in disease affecting chromatin structure, a combination of transcriptional machinery preloaded across the genome, or, as found in disease, up to 50% of loci displaying pre-existing differences in epigenetic signatures influencing this response. Furthermore, the state of chromatin compaction may play an important role. About half of EREs are in regions of DNA with open chromatin prior to estrogen induction \[[@pgen.1008601.ref067]\], but many ERα binding sites in open chromatin are associated with differentially expressed genes after estrogen induction. These data indicate that chromatin compaction can directly affect ERα recruitment and subsequently target gene transcription. Thus, pre-existing and distinct differential methylation observed in stage I and stage IV can potentially affect chromatin compaction in patients with endometriosis. This is currently under investigation in our laboratory.

ERα can be activated by phosphorylation by growth factors binding to tyrosine kinase receptors such as EGFR \[[@pgen.1008601.ref068]\], which were dysregulated in the current study. Genes targeted by phosphorylated ERα are distinct from those targeted by estrogen-induced ERα activation \[[@pgen.1008601.ref069]\]. Signaling through EGFR is a key pathway in eSF response to E~2~, and constitutive activation of EGFR in eSF from women with endometriosis has been reported \[[@pgen.1008601.ref070]\]. Inhibition of EGFR in eSF from women with disease restores decidualization markers \[[@pgen.1008601.ref071]\], underscoring the complexity of the interplay between E~2~ and P~4~ signaling in eSF in endometrium of women with endometriosis. The data overall support phosphorylation of ERα in eSF treated with E~2~ may contribute, in part, to differential DNA methylation signatures and gene expression profiles observed in E~2~ versus E~2~+P~4~ in women without and with disease, which remains to be proven experimentally. Interestingly, E~2~ and EGF can induce ERα recruitment at three classes of enhancers \[[@pgen.1008601.ref072]\], bound only with EGF stimulation, only with E~2~ stimulation, or either. Herein, enrichment of enhancer involvement upon E~2~ stimulation and with E~2~+P~4~ was observed in normal eSF as well as eSF from women with both stages of disease, but with different effects on downstream target genes. We propose that even small differences in EGFR signaling pathways could greatly alter the eSF responses to hormones, as observed herein.

Study strengths and limitations and future directions {#sec025}
-----------------------------------------------------

In this study, effects of E~2~, P~4~ and their combination were elucidated on genome-wide DNA methylation marks of the endometrial stromal fibroblast, the predominant cell type in human endometrium essential for establishing and continuing pregnancy. The clinical phenotyping of truly normal controls and specific, well-phenotyped disease stages is a great strength of this study. Also, using the same cells for DNA methylation and gene expression analyses also added to the robustness of the data. Moreover, comparisons of the data herein with published gene expression and DNA methylation data in bulk tissue underscore signatures in the latter due to this predominant cell type. Single cell analysis of eSF from bulk tissue by FACS further underscores the signature of this cell type in overall bulk tissue analyses and opens the door for single cell RNA-Seq and DNA-me analyses in the future.

While use of an *in vitro* system can address whether/how steroid hormones directly affect the eSF epigenome, an *in vivo* model using freshly isolated, sorted endometrial cells would offer an opportunity to assess functionality of the ER and PR landscape in human eSF and other endometrial cell types. Primary epithelial cells were not viable in culture when treated with hormones and as such we did not expand the current study involving epithelial cells, but organoid systems may offer a tool for this investigation. Further analysis using chromatin immunoprecipitation followed by deep sequencing of ER and expanding on the PR binding sites by Mazur *et*.*al* \[[@pgen.1008601.ref010]\], identification of ERE and PRE-specific to endometrium and the status important to pioneer and co-activators and in a larger sample size are required for detailed mapping of the steroid hormone landscapes and hormone-epigenome interplay in normal human endometrial cells and in disease. Transcriptome data from the same cells demonstrate extensive overlap with previously identified differentially expressed genes in whole tissue in the corresponding hormone milieu. We note that utilizing microarray instead of a more comprehensive transcriptome analysis such as RNA-Seq limited the number and the type of transcripts investigated herein. Furthermore, protein data will enable full assessment of epigenomic and transcriptomic effects of hormones in endometrial function normally and in women with endometriosis. An important limitation of this study is the small sample size in each group. We had used very strict criteria for sample selection, both in identifying normal samples without any gynecological and pelvic disease/disorder and for endometriosis to not have any other disease no matter how benign, such as uterine fibroids. A follow up study with a much larger sample size is required to confirm our observations.

Overall this study has elucidated the array of responses of eSF in health and disease in hormone milieu encountered in cycling women that can also serve for comparisons with actions of pharmaceutical steroids used clinically and potentially environmental estrogens that can compromise reproductive function. Moreover, the data reveal unique responses and pre-existing epigenetic abnormalities in women with endometriosis that can benefit endometrial-based diagnostic development and novel targeted therapies for endometrial dysfunction in women with this disorder.

Materials and methods {#sec026}
=====================

Ethics statement {#sec027}
----------------

This study was approved by the Committee on Human Research of the University of California, San Francisco (UCSF) (IRB\# 10--02786). All samples were collected after written informed consent was obtained from all subjects.

Samples {#sec028}
-------

Eutopic (within the uterus) endometrial tissue samples were collected through the UCSF/NIH Human Endometrial Tissue/DNA Bank. Stringent inclusion criteria were applied as follows: I) for normal controls, samples were collected from oocyte donor volunteers with no uterine or pelvic pathology (NUP, normal controls); endometriosis samples were collected from stage I and stage IV endometriosis patients (**[S18 Table](#pgen.1008601.s021){ref-type="supplementary-material"}**). Oocyte donor volunteers (controls) were extensively screened, had no gynecologic disorders, and donated endometrial samples six months post oocyte retrieval. Endometriosis patients (stage I and IV) were surgically confirmed and had no other gynecologic abnormalities. II) All samples were collected in the proliferative phase and matched for age, BMI, no smoking history (one exception), no contraceptive steroid use three months prior to sample collection, and endometrial stromal fibroblast (eSF) passage number. Menstrual cycle phase was determined by histological evaluation \[[@pgen.1008601.ref073]\] as well as serum levels of E~2~ and P~4~. Disease stage was determined by ASRM criteria \[[@pgen.1008601.ref074]\].

Stromal cell isolation and hormone treatment {#sec029}
--------------------------------------------

Primary eSF were isolated from endometrial biopsies by digestion with collagenase and size fractionation as described \[[@pgen.1008601.ref075]\] and cultured as monolayers in stromal cell medium (SCM, \[[@pgen.1008601.ref018],[@pgen.1008601.ref019],[@pgen.1008601.ref076]\]). To ensure the purity of stromal cells in culture, after digestion of endometrial sample biopsies, the digested tissue was size fractionated using a 40μM filter to separate epithelial glands, followed by stromal cells selective attachment and growth in stromal cell medium. The purity of primary eSF was monitored morphologically during the culture and the homogeneity was verified by immunocytochemical localization of vimentin for eSF, keratin for epithelial cells and actin for vascular cells \[[@pgen.1008601.ref076]\] before further hormone experiments. Only pure primary eSF (with \<0.1% other cells) were used for this study. After 24 hours serum starvation, eSF from normal women (n = 7, controls) and endometriosis women (n = 6 stage I, n = 9 stage IV) were treated with four different hormonal treatments of 10 nM E~2~, 1μM P~4~, 10 nM E~2~ +1μM P~4~, or vehicle (0.1% ethanol) control for 14 days \[[@pgen.1008601.ref076]\]) after which conditioned media and cells were collected for further analysis. Decidualization was assessed in E~2~+P~4~ treated eSF from normal, stage I and stage IV disease (see below). As eSF from women without endometriosis mostly have a robust decidualization response to E~2~+P~4~, our controls were eSF that fully decidualized (n = 4) by the decidualization marker IGFBP1 by ELISA and morphologically. As rarely do eSF from endometriosis women decidualize *in vitro* in response to E~2~+P~4~, eSF from stage I (n = 4) and stage IV (n = 4) with non-detectable decidualization (the most common phenotype) by morphology and IGFBP1 marker by ELISA were used for further analysis.

Decidualization assessment {#sec030}
--------------------------

Insulin-like growth factor binding protein-1 (IGFBP1), a P~4~-induced decidualization marker \[[@pgen.1008601.ref077]\], was measured in media conditioned by 14 day E~2~+P~4~ treated cultures, by ELISA (Alpha Diagnostic International Inc., San Antonio, TX) as a marker for decidualization. Concentrations were measured in duplicate, averaged and normalized to cell number. eSF were assessed by microscopy for morphological changes corresponding to decidualization.

DNA and RNA extraction {#sec031}
----------------------

After treatments cells were harvested, pelleted and frozen at -80C for DNA and RNA extraction as previously described \[[@pgen.1008601.ref014],[@pgen.1008601.ref015]\]. Genomic DNA was extracted using QIAGEN (QIAamp DNA Tissue Kit, QIAGEN, Germantown, MD) and RNA was extracted using the Macherey-Nagel NuceloSpin Tissue Kit with DNase treatment (Macherey-Nagel Inc., Bethlehem, PA) according to manufacturers' recommendations and stored at -80C.

DNA methylation {#sec032}
---------------

Genomic DNA was bisulfite converted at the University of Southern California (USC) Epigenome Center using the EZ-96 DNA Methylation Kit (Zymo Research, Irvine, CA), according to the manufacturer's protocol, and as previously described \[[@pgen.1008601.ref014],[@pgen.1008601.ref015]\]. Quality, completeness of bisulfite conversion and amount of bisulfite-converted DNA were assessed by a panel of MethyLight reactions \[[@pgen.1008601.ref078]\]. All samples passed all quality controls (QCs) and were further assayed by the Illumina Infinium HumanMethylation450K DNA methylation platform (HM450) based on Illumina's specifications. (All data files are submitted to GEO, under SuperSeries accession number GSE145702).

Gene expression microarray analysis {#sec033}
-----------------------------------

RNA quality was assessed by Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). RNA samples were prepared for microarray analysis according to Affymetrix (Affymetrix, Inc., Santa Clara, CA) specifications \[[@pgen.1008601.ref015]\]. cDNA sample quality was assessed by Bioanalyzer, and samples passing QCs were hybridized to Affymetrix HU133 Plus 2.0 gene array, interrogating \>38,500 genes at the UCSF Genomics Core.

DNA methylation data analysis {#sec034}
-----------------------------

HM450 interrogates 485,577 methylation targets across the genome. The ratio of methylated signal over total fluorescent signal was used to calculate β values, ranging from 0 (no) to 1 (complete) methylation. 850 control bead types were used as positive and negative controls and to calculate a detection P value to assess DNA methylation measurement quality for each probe of each sample \[[@pgen.1008601.ref079]\]. The passing threshold of P value was set at P\<0.05, and probes with P\>0.05 were indicated as "missing" (no statistically significant differences from background). Probe dropout-rates (percent probes with missing values versus total number of platform probes) were calculated to exclude samples with dropout-rates \>1%. All 12 samples passed these criteria. Probes with a "missing" value in \>1 sample were removed. Differential DNA methylation in each hormone treatment in each group (control, stage I, stage IV) was identified compared to non-treated cells (vehicle control) in the same group. For each probe, β values of hormone treatment in an individual sample were compared to its corresponding vehicle treated β value (Δβ). Changes in β values (Δβ) \< 10% were not considered as differentially methylated for each sample. Median or average changes between hormone treatment vs vehicle control were not used, to obviate limited numbers of strong signals affecting selecting differentially methylated loci. Instead, probes were considered differentially methylated if they exhibited \>10% change in β value (Δβ \>10%) in hormone treatment versus vehicle *and* in at least 3 of 4 samples within each group, *and* with the same direction of methylation change (gain or loss). To assess if the aberrant signatures observed in hormone induced changes in disease compared to normal were due to pre-existing aberrations in the non-treated cells, we compared the methylation signatures of the non-treated (vehicle) eSF in each disease stage to non-treated (vehicle) eSF in normal for each aberrantly methylated locus in response to each hormone in disease. Pre-existing differential methylation, loci differentially methylated in normal vs each stage of disease in untreated cells (vehicle) were determined. The percentage of the differences observed in hormonal treatment of disease were assessed. Association of CpG islands with enhancers, distribution across the genome, association with CGIs and CGI shores and shelves were extracted from Illumina Infinium HumanMethylation450K manifest.

Gene expression analysis {#sec035}
------------------------

The raw.CEL gene expression data files were RMA normalized using GeneSpring (GX13.1 version, Agilent Technologies). Loci were considered differentially expressed with Benjamini-Hochberg corrected ANOVA p\<0.05 and fold change (FC)≥1.5 in each comparison.

DNA methylation association with changes in gene expression {#sec036}
-----------------------------------------------------------

Differentially methylated loci and normalized gene expression were imported into R, and corresponding probes from each platform were matched using the transcript identifier. Every DNA methylation probe for a given locus identifier was compared to all corresponding transcripts of that locus using the non-parametric Spearman's rank-order correlation method, as bivariate normality could not be assumed (DNA methylation data are not normally distributed). Spearman\'s rank correlation coefficients (ρ) on gene expression and DNA methylation were computed for each probe, along with a p value testing against the null hypothesis that ρ equals zero.

Pathways, biofunctions and genomic distribution analyses {#sec037}
--------------------------------------------------------

Ingenuity Pathway Analysis (IPA, QIAGEN) software was used to determine pathways, upstream regulators and biofunctions of differentially expressed genes, as described \[[@pgen.1008601.ref014],[@pgen.1008601.ref015],[@pgen.1008601.ref026]\]. Pathways with Z-scores ≥\|2\| were considered significantly enriched. For differentially methylated loci, DAVID and KEGG databases were used to identify functional classification, functional enrichment and pathways. For pathway selection an enrichment score ≥\|2\| with a Benjamini-Hochberg corrected p\<0.05 was considered. For genomic distribution, element enrichment analyses, the null hypothesis that the observed proportions in two groups are the same, a test of proportions was performed in R using the prop.test() function.

Association of *in vitro* and *in vivo* differential gene expression {#sec038}
--------------------------------------------------------------------

eSF treatment with E~2~ and E~2~+P~4~ used herein, mimicked *in vivo* proliferative endometrium (PE, E~2~-dominant phase) and mid-secretory endometrium (MSE (E~2~ and P~4~- dominant phase). To assess commonalities, the current data were compared to previously published \[[@pgen.1008601.ref026]\] whole endometrial gene expression in PE and MSE in normal versus disease. E~2~-treated differential expression in eSF from stage I versus control and stage IV versus control were compared to endometriosis (all stages) versus control in bulk tissue PE, and E~2~+P~4~- treated compared to MSE. FACS-sorted eSF gene expression data \[[@pgen.1008601.ref020]\] in disease versus control were also compared. As FACS-sorted eSF~endo~ and eSF~normal~ included a mixture of phases and endometriosis stages, gene expression signatures of FACS-sorted eSF were compared to stage I, stage IV eSF treated with E~2~ and E~2~+P~4~.

ChIP-Seq for Histone H3K27me3 and H3K27ac in response to E~2~ {#sec039}
-------------------------------------------------------------

We found that E~2~ affected the methylome more robustly than P~4~ or E~2~+P~4~ and that, unexpectedly, along with aberrant P~4~ response in disease, E~2~ response was also aberrant in both stages of disease. Therefore, we sought to investigate further the effect of E~2~ on two repressive and open chromatin histone marks, H3K27me3 and H3K27ac. eSF cells from two independent control participant were isolated from endometrial biopsies by digestion followed by size fractionation, and primary eSF were cultured in SCM and purity of cultured eSF was assessed as described above. eSF was passaged with trypsin and 1x10^5^ cell/well were seeded. Confluent cultures were serum starved for 24hrs and treated with E~2~ or vehicle for 14 days. Cells were cross-linked by a final concentration of 1% formaldehyde and terminated after 10 minutes by 0.125 M final concentration glycine. Chromatin was extracted using Chromatin Extraction Kit according to manufacturer's recommendation (ab117152, Abcam, Cambridge, UK) sonicated by Diagenode Bioruptor and the size of sheared chromatin was visualized on agarose gel (100-600bp). Chromatin Immunoprecipitation was done using Abcam ChIP Kit (ab117138, Abcam, Cambridge, UK) with antibodies for H3K27me3 (ab6002, Abcam, Cambridge, UK) or H3K27ac (ab4729, Abcam, Cambridge, UK). Input control and immunoprecipitated DNA were paired-end sequenced using Illumina NextSeq 500 after library preparation according to the manufacturer's instructions. Data were analyzed by removing adapter sequences, then aligned to reference human genome. Peaks called using Macs2 *callpeaks* and were selected with q-value \<0.05. Differential peaks were identified using Macs2 *bdgdiff* and log likelihood ratio \>3.
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